

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092635 A2

- (51) International Patent Classification⁷: **C07K 16/28**, 16/30, C12N 15/12, A01K 67/027, C12N 15/79, 5/10, A61K 39/395, C07K 19/00, A61P 35/00, G01N 33/50
- (74) Agent: **AXFORD, Laurie, A**; Morrison & Foerster LLP, 3811 Valley Centre Drive, Suite 500, San Diego, CA 92130-2332 (US).
- (21) International Application Number: **PCT/IB02/02887**
- (22) International Filing Date: **1 May 2002 (01.05.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
09/847,102 **1 May 2001 (01.05.2001)** **US**
- (71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Transfer, 5th Floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).
- (72) Inventors: **RHEE, Chae-Seo**; 12510 Carmel Creek Road, San Diego, CA 92130 (US). **SEN, Malini**; 3455 Lebon Drive, #1635, San Diego, CA 92122 (US). **LEONI, Lorenzo, M.**; 3908 Via Tranquilo, San Diego, CA 92122 (US). **CORR, Maripat**; 10686 Mira Lago Terrace, San Diego, CA 92131 (US). **CARSON, Dennis, A.**; 14824 Vista Del Oceano, Del Mar, CA 92014 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *without international search report and to be republished upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **IMMUNOLOGIC COMPOSITIONS AND METHODS FOR STUDYING AND TREATING CANCERS EXPRESSING FRIZZLED ANTIGENS**

Sequence alignment of a portion of the aminoterminal extracellular region of human Frizzled receptors

HF21	VGQNTSDKGT---PSLLPEFWTSNPQHGGGCHRG-----	GFPGGAG---ASERGFESCPR
HF22	VGQNHSEDCG-----PALTTAPPPGLPGAGGTPG-----	GPGGGAPPYATLEHPFHC
HF23	LVDLNLG-----EPTGAPV-----	AVQRDYG-----FWC
HF24	CMEGPGD-----EE-----	VPLPKTPI-----QP
HF25	CMYNRSEATTAPPRFPAPKPTLPG-----PPGA-----	PASGG---ECPAGGPFV-----CKC
HF26	TFDPHTEF-----LGPQKTE-----	QVQRDIG-----FWC
HF27	VGQNTSDGSGGPGGGPTAIPYLPDLPTALPPG-----	ASDGRGRPAF-----PFSC
HF28	CMYNRDLDLTTAAPSPPRRLPPPP-GEQPPSGSCHGRPPGARPPHGGGGRGGGGDAAAPPARGGGGGKARPPCGGAAP---	CEPGCQC
HF29	CMEAPENA-TAGPAEPHKGLMLPV-----	APRPAPPG-----DLGP
HF210	NYLCMEAPNN---GSDEPTRGSGLFPP-----	LFRPQRPHSAQ-----EHP

(57) Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.

WO 02/092635 A2

IMMUNOLOGIC COMPOSITIONS AND METHODS FOR STUDYING AND TREATING CANCERS EXPRESSING FRIZZLED ANTIGENS

TECHNICAL FIELD

This invention is in the field of immunology. More specifically, it relates to
5 compositions and methods for identifying, treating and preventing cancer by targeting the
extracellular domains of the frizzled receptor family of proteins.

BACKGROUND OF THE INVENTION

Many adult cancers arise from small populations of residual tissue stem cells that
have a high rate of cell proliferation. These tissue stem cells express various different cell
10 surface receptors and ligands that are used to direct tissue pattern formation and cellular
differentiation during development of the embryo, but since these receptors and ligands are
not needed in adults, their expression is often very low in differentiated cells. Thus,
targeting the immunological differences between the receptors that are expressed by
cancers arising-from residual tissue stem cells and those found on normal cells may provide
15 for useful cancer therapies.

In order for cell surface receptors and their associated ligands to be suitable targets
for immunotherapies, they should have certain preferred characteristics. First, they should
be expressed on the surface of the malignant cells, and to a much lesser degree on normal
cells. Second, they should have areas of secondary structures that give rise to
20 conformations which are capable of being recognized by antibodies, cytotoxic T cells
and/or drugs. Third, these areas of recognition should be sufficiently different from other
cell surface receptors to avoid potentially damaging immunologic cross-reactions.

The G-protein coupled receptors (GPCRS) are particularly attractive targets for both passive and active immunotherapy, because many of these receptors have all three of these characteristics. In general, they contain seven membrane-spanning regions and a relatively short amino-terminal tail that is exposed into the extracellular environment. This "tail" often assumes a defined secondary structure which is unique to each receptor. In addition to the tail portion, there are other regions in-between the membrane-spanning regions that are also exposed on the cell surface. Accordingly, members of this gene family may be attractive targets for active and passive immunotherapies.

Frizzled antigens are a family of GPCR-like receptors that have binding sites for Wnt protein ligands, which are secreted molecules that act as upregulators of gene expression via the 0-catenin cytoplasmic intermediate pathway. This receptor-ligand pair plays a role in embryonic development, and may play a role in cellular proliferation and the ultimate fate of cells during embryogenesis.

The presence of frizzled gene products in human cancer cells has previously been suggested. For example, frizzled-2 (FRZ-2) was originally isolated by Sagara et al., who reported that mRNA from frizzled-2 was not detectable in 15 different normal human adult tissues, with the possible exception of heart tissue, but was found in embryonic tissues, as well as six of eight malignant cell lines (Biochem. Biophys. Res. Comm. 252:117-122 (1998)). However, the ultimate expression of the mRNA and the presence of particular frizzled antigens in cancer cells but not in normal cells has not been described.

There are 18 Wnt and 10 Frizzled genes, all of which are highly homologous in structure, which have been identified thus far from the human genome database (Science, 291:1304-1351 (2001)). However, their high degree of homology and the existence of mRNA encoding these receptors in both normal and tumor tissue would suggest that they would not make a suitable target for immunotherapies.

Despite their homology and widespread existence, it would be expected that there are certain frizzled proteins that are highly specific for tumors. This is because of their involvement in embryogenesis and the hypothesis that many malignant cells may express

embryonic patterning receptors. Accordingly, the present invention relates to the design of immunologic compositions and methods that target the portion of the frizzled antigen that is unique to this protein, specific to cancer cells, and also exposed on the cell surface.

SUMMARY OF THE INVENTION

5 The present invention relates, *inter alia*, to a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein the antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell. In a preferred embodiment, this extracellular domain comprises the amino terminal peptide fragment of the frizzled receptor. The
10 antibody can further comprises an in-tact antibody or a fragment thereof as described in more detail herein. The purified antibody can also be capable of sensitizing malignant cells expressing the frizzled receptor to a cytotoxic factor. It is also possible that binding of the antibody to the receptor inhibits binding of the Wnt ligand.

 For use in a diagnostic assay, the purified antibody of claim I may further comprise
15 a detectable label. In another aspect of the present invention, the antibody may be a human antibody, and may be polyclonal or monoclonal antibody.

 In another embodiment, the present invention relates to an isolated nucleic acid, comprising at least one nucleotide fragment encoding an extracellular domain of a frizzled receptor that serves as an epitope for the antibody just described. In instances when it is
20 necessary to enhance the immunogenicity of the frizzled receptor epitope, one can couple the epitope to a known T cell epitope, such as the tetanus toxin. Accordingly, a frizzled receptor epitope conjugate can be prepared comprising at least one epitope in an extracellular domain of the frizzle receptor expressed on a malignant cell and at least one epitope specific to a T cell antigen. It is also possible to enhance the immunogenicity of
25 any given frizzled receptor epitope by preparing a multimer, such as a dimer or trimer,

thereof. Such conjugates can be prepared by direct conjugation, or by making use of a linker moiety, such as the GPSL linker.

Another aspect of the present invention relates to a transgenic non-human animal which has been transfected with the nucleic acid encoding the frizzled receptor, or a portion thereof. The present invention also relates to a recombinant vector, comprising at least one nucleic acid encoding the frizzled receptor, or a portion thereof, functionally attached to a promoter region upstream of the nucleic acid. In addition, the present invention relates to a host cell comprising at least one such recombinant vector.

In yet another aspect of the present invention, a pharmaceutical composition is provided which comprises a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein the antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.

The present invention also relates to a method for modulating a biological activity of a malignant cell that expresses a frizzled receptor comprising administering a pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein the antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.

In a further embodiment, the present invention relates to a pharmaceutical composition useful as a vaccine against malignancy for administration to a patient having a predisposition for the malignancy, wherein the antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell. Such vaccine can be administered using a method of immunizing a subject against a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:

a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least

one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell; and

b) administering the antibody in a pharmaceutically acceptable carrier in an amount sufficient to inhibit the malignancy.

5 For use as an immunotherapeutic agent, the present invention relates to a method of treating a subject with a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:

a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least
10 one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell; and

b) administering the antibody in a pharmaceutically acceptable carrier in an amount sufficient to modulate a biological activity of the malignant cell.

For use as an immunoassay, the present invention relates to an assay for identifying
15 a frizzled receptor expressed by a malignant cell, wherein said frizzled receptor comprises at least one epitope in an extracellular domain, comprising the steps of:

a) identifying an antibody that specifically binds to the epitope;

b) exposing a sample of cells suspected of expressing the frizzled receptor to the antibody; and

20 c) determining the extent of binding of the antibody to the cells.

In yet another aspect of the present invention, a screening assay is provided for identification of small molecules that modulate frizzled receptor activity, which comprises:

a) selecting a library of the small molecules comprising a plurality of different chemical structures;

25 b) contacting the small molecules with an extracellular domain of a frizzled receptor which is capable of binding to its corresponding Wnt protein; and

c) measuring binding of a ligand to the frizzled receptor in the presence of the small molecule, wherein the ligand is selected from the group consisting of the small

molecule, the Wnt protein, and an antibody to the extracellular domain of the frizzled receptor. Such small molecules, which may be nucleic acids, peptides, small organic molecules, or combinations thereof, can function by competing with the Wnt protein for binding to the frizzled receptor, or may mimic the frizzled receptor and bind to the Wnt protein, wherein in the latter instance, the small molecule will prevent binding of both the Wnt protein and an antibody that is specific for the frizzled receptor epitope to which the Wnt protein normally binds from binding thereto. These types of screening methods are well known in the G-protein coupled receptor field, and in particular the field of odorant receptors. See, e.g., U.S. Patent No. 6,008,000, which discloses assays for screening taste modulating small molecules that modulate the activity of a G-protein coupled receptor known to be associated with taste.

Other aspects of the present invention are found throughout the specification.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a schematic of the developmental signaling pathways.

Figures 2A - 2D depict the alignment of various deduced amino acid sequences of frizzled receptors derived using the Clustal W program on DeCypher. "CY" refers to the cysteine rich domain. "TM" refers to the transmembrane domain. Accordingly, the regions in-between the CRD and TM domains represent the extracellular regions.

Figure 3 depicts the sequence alignment of a portion of the first extracellular region of human frizzled receptors.

Figure 4 depicts the proliferation of SNU1076 cells as described in Example 3

Figures 5 and 6 depict the effects of anti-Fz Abs on cancer cell apoptosis as described in Example 4.

Figure 7 depicts a graphical representation of an olfactory protein, also a G-protein coupled receptor transmembrane protein like the frizzled receptors, showing the amino

terminal and three extracellular domain loops, as well as the seven transmembrane domains shown within the cylinders (from PCT WO 92/17585).

Figures 8A - 8I depict the sequence alignment of the deduced amino acid sequences of human (HFZ) and mouse (MFZ) frizzled receptors 1 to 10, assigned Seq. ID No.s. 44 to 60 in the order shown. Also depicted therein are the amino terminal domains (assigned Seq. ID No.s 61 to 77 in the order shown), the extracellular domain loop 1 (assigned Seq. ID No.s 78 to 94 in the order shown), the extracellular domain loop 2 (assigned Seq. ID No.s 95 to 111 in the order shown), and the extracellular domain loop 3 (assigned Seq. ID No.s 112 to 128 in the order shown).

10

DISCLOSURE OF THE INVENTION

The present invention relates to the use of immunologically unique frizzled receptor epitopes as binding targets in the design of compositions and methods that are useful in immunologic based diagnostics and therapeutics of cancers associated with overexpression of frizzled receptors.

15

In embryogenesis, body patterning is related to the axial expression of different proteins. The proximal-distal axis is controlled by fibroblast growth factor (FGF), anterior-posterior axis by Sonic hedgehog (SHH), and the dorsal ventral axis by wingless (Wnt). These factors are closely cross-regulated in development. As shown in Figure 1, the secretion of Wnt is stimulated by SHH signaling and conversely the expression of SHH is supported by the continued presence of Wnt. SHH in turn influences FGF expression. Wnt has been shown to be a ligand for a G-coupled protein receptor in the frizzled (Fz) family of receptors, which mediates a complex signaling cascade. Transcriptional regulation is also mediated by SHH cell surface interaction with its ligand, Patched. Patched tonically inhibits signaling through Smoothened until it binds to SHH. The Wnt/frizzled pathway has been previously implicated in tumorigenesis. Soluble Wnt glycoproteins have been demonstrated to transmit signal by binding to the seven transmembrane domain G-protein

20

25

coupled-receptor (Figure 1). Upon Wnt signaling, a cascade is initiated that results in the accumulation of cytoplasmic beta-catenin and its translocation to the nucleus. In the nucleus beta-catenin binds a specific sequence motif at the N terminus of lymphoid-enhancing factor/T cell factor (LEF/TCF) to generate a transcriptionally active complex.

- 5 Beta-catenin interacts with multiple other proteins such as cadherin which it links to the cytoskeleton. It also associates with the adenomatous polyposis coli (APC) tumor suppressor protein and glycogen synthetase 3 beta (GSK3 β). These proteins function to negatively regulate beta catenin by facilitating phosphorylation near the aminotermminus and thus accelerating its proteolytic degradation.

- 10 The frizzled receptors are a well-characterized family of transmembrane receptor proteins. To date, there are ten known human frizzled proteins that have been identified from the human genome as follows:

Table I
Known Human Frizzled Genes

Gene	Chromosome	Reference
FZD1	7a21	Sagara (1988)
FZD2	17q21.1	Zhao Z (1985), Sagara (1988)
FZD3	8p21	Kirikoshi (2000), Sala 2000
FZD4	11q14-q21	Kirikoshi (1999)
FZD5	2q34	Wang Y (1996)
FZD6	8q22.3-q23.1	Tokuhara (1998)
FZD7	2q33	Sagara (1988)
FZD8	10	genome
FZD9	7q11.23	Wang, YK (1997)
FZD10	12q24.333	Koike, et al. (1999)
SMOH	7q31-32 Xie 1998	Stone (1996)
FZE3	This gene could be the same as FZD7	Tanaka, et al. (1998)

1. Sagara, Biochem. Biophys. Res. Commun. 252(1): 117-122 (1998)
2. Zhao, Genomics 27(2): 370-373 (1995)
3. Kirikoshi, Biochem. Biophys. Res. Commun. 27(1): 8-14 (2000)
4. Sala, Biochem. Biophys. Res. Commun. 273(1): 27-34 (2000)
5. Kirikoshi, Biochem. Biophys. Res. Commun. 264(3): 955-961 (1999)
6. Wang, J. Biol. Chem., 271(8): 4468-4476 (1996)
7. Tokuhara, Biochem. Biophys. Res. Commun. 243(2): 622-627 (1998)
8. Wang, Hum. Mol. Gen. 6(3): 465-472 (1997)
9. Koike, Biochem. Biophys. Res. Commun. 262(1): 39-43
10. Stone, Nature 384(6605): 129-134 (1996)
11. Tanaka, Proc. Nat. Acad. Sci. 95(17): 10164-10169 (1998)

The alignment of several of these frizzled receptors is shown in Figure 2. As shown therein, Seq. ID No. 35 is assigned to fz3/mouse; Seq. ID NO. 36 is assigned to fz4/mouse; Seq. ID No. 37 is assigned to fz8/mouse; Seq. ID NO. 38 is assigned to fz5/human; Seq. ID No. 39 is assigned to fzd9/human; Seq. ID No. 40 is assigned to fzd1/rat; Seq. ID No. 41 is

assigned to *fzd2*/rat; Seq. ID No. 42 is assigned to *fz*/Dros; and Seq. ID No. 43 is assigned to *fz*/Dros.

To evaluate frizzled receptors for their potential as tumor-associated antigens, various hematologic and epithelial tumors are screened by amplifying the mRNA in the tumor cells using a known amplification method, such as reverse-transcription-polymerase chain reaction (RT-PCR) using primers that are specific for known frizzled receptor-associated sequences. From the results of this initial screening, subregions of the nucleic acid sequence are identified that encode the extracellular regions of the frizzled receptor and are further amplified. The sequence alignment of a portion of the first extracellular region is shown in Figure 3. This extracellular amino terminal domain is generally regarded as antigenic, because of its size and ternary structure.

As mentioned elsewhere herein, the gene sequences of frizzled receptors 1 to 10 are known. Also, as shown in Figure 8, the sequence alignment of the deduced amino acid sequences of human (HFZ) and mouse (MFZ) frizzled receptors 1 to 10 have been determined, and assigned Seq. ID No.s. 44 to 60 in the order shown. Also depicted therein are the amino terminal domains (assigned Seq. ID No.s 61 to 77 in the order shown), the extracellular domain loop 1 (assigned Seq. ID No.s 78 to 94 in the order shown), the extracellular domain loop 2 (assigned Seq. ID No.s 95 to 111 in the order shown), and the extracellular domain loop 3 (assigned Seq. ID No.s 112 to 128 in the order shown.) For example, Seq. ID No. 95 corresponds to the extracellular domain loop 2 for the HFZ1 receptor shown in Figure 8c, which is:

Seq. ID No. 95: GQVDGDVLSGVCFVGLNNVDALRGF

For convenience, the Seq. ID No. assignments to the human extracellular domains given in Figure 8 are shown below in Table II:

Table II

Sequence ID No.s of Extracellular Domains of Human Receptors given in Figure 8

Frizzled #	Entire Seq.	Amino Terminal	Loop 1	Loop 2	Loop 3
1	44	61	78	95	112
2	46	63	80	97	114
3	47	64	81	98	115
4	49	66	83	100	117
5	51	68	85	102	119
6	52	69	86	103	120
7	54	71	88	105	122
8	56	73	90	107	124
9	58	75	92	109	126
10	60	77	94	111	128

1. Primers

- 5 A primer is preferably single stranded for maximum efficiency, but may alternatively be in double stranded form. If double stranded, the primer is first treated to separate it from its complementary strand before being used to prepare extension products. Preferably, the primer is a polydeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the agents for
- 10 polymerization. The exact lengths of the primers will depend on many factors, including temperature and the source of primer.

Exemplary primer pairs for known human frizzled genes are shown below in Table II.

Table II
PCR Primers for Known Human Frizzled Isoforms

		Forward Primers 5' >3'
Seq. ID 1	Frizzled 1	CCCAGAGCTGCAAGAGCTAC
Seq. ID 2	Frizzled 2	GCCGTGCCGCTCTATCTGTGAG
Seq. ID 3	Frizzled 3	ATAGGCCTGATCATCTGAATCTCCTTCA
Seq. ID 4	Frizzled 4	AACCTCGGCTACAACGTGAGACCAAGAT
Seq. ID 5	Frizzled 5	ATCGGCTACAACCTGACGCACA
Seq. ID 6	Frizzled 6	TCTGGAATGTTACCAAACATTGAAACT
Seq. ID 7	Frizzled 7	CTCATGAACAAGTTCGGCTTCCAGT
Seq. ID 8	Frizzled 8	GATGAGGATGAGAGTGAGGTGACATCC
Seq. ID 9	Frizzled 9	CACGCGCTGTGCATGGAG
Seq. ID 10	Frizzled 10	CATGGAGGCGCCCAACAAC
		Reverse Primers 5'>3'
Seq. ID 11	Frizzled 1	CACGATCAGCGTCATAAGGT
Seq. ID 12	Frizzled 2	GTGGCGCGGGAAGTGCTC
Seq. ID 13	Frizzled 3	TCTTGGCACATCCTCAAGGTAATAGGTT
Seq. ID 14	Frizzled 4	GTA CTGGATGAGCGGTGTGAAAGTTGT
Seq. ID 15	Frizzled 5	ATGGGCGTGTACATAGTGCATAGGAAG
Seq. ID 16	Frizzled 6	TTTCTCATAAAGTTTACGACAAGGTGGA
Seq. ID 17	Frizzled 7	CGCGGTAGGGTAGGCAGTGG
Seq. ID 18	Frizzled 8	ACTCAGACTTCCTGGCTCTCAGGTG
Seq. ID 19	Frizzled 9	GGCTCTTCTCCACGTACTGGA ACTTCT
Seq. ID 20	Frizzled 10	CTCCTTCAGCGGGTGCTCCT

- 5 The primers described herein are selected to be "substantially" complementary to the different strands of each specific sequence to be synthesized or amplified. This means that the primer must be sufficiently complementary to hybridize relatively specifically with its intended primer site in the target template strand. Therefore, the primer sequence may or may not reflect the exact sequence of the template. For example, a non-complementary
- 10 nucleotide fragment can be attached to the 5' end of the primer, with the remainder of the primer sequence being substantially complementary to the strand. Such non-complementary fragments typically contain an endonuclease restriction site. Alternatively, non-complementary bases or longer sequences can be interspersed into the primer, provided the primer sequence has sufficient complementarity overall with the sequence of

the strand to be synthesized or amplified to non-randomly hybridize therewith and thereby form an extension product under polynucleotide synthesizing conditions.

A frizzled gene-specific primer preferably includes at least about 15 nucleotides, more preferably at least about 20 nucleotides. The primer preferably does not exceed about 30 nucleotides, more preferably about 25 nucleotides, although it can contain fewer nucleotides. Short primer molecules generally require lower temperatures to form sufficiently stable hybrid complexes with the template. Most preferably, the primer includes between about 20 to about 25 nucleotides. The length of the primer will vary inversely with the extent of conservation of the complementary exon sequence. The GC content of the primers should be about 50%.

Primers can be prepared using a number of methods, including phosphotriester and phosphodiester methods or automated embodiments thereof. The phosphodiester and phosphotriester methods are described in Cruthers, *Science*, 230:281-285 (1985); Brown et al., *Meth. Enzymol.*, 68:109 (1979); and Nrang et al., *Meth. Enzymol.*, 68:90 (1979). In one automated method, diethylphosphoramidities which can be synthesized as described by Beaucage et al., *Tetrahedron letters*, 22:1859-1962 (1981) are used as starting materials. A method for synthesizing primer oligonucleotide sequences on a modified solid support is described in U.S. Pat. No. 4,458,066.

Primer extension reactions are preferably performed using purified DNA from the target organism. Isolation of DNA from cells is routine in the art and there are numerous sources of nucleic acid isolation protocols suited for microorganisms such as bacteria and fungi including mammalian cells (e.g., Sambrook et al., *supra*, (1989)). Primer extension reactions also can be performed using DNA that has not been purified but is accessible to the primer. The DNA can be accessible naturally in the sample or can be made accessible following one or more processing steps.

2. Amplification

The frizzled gene amplifying primers are used to amplify products from tumor cells in a primer extension reaction. A variety of primer extension reactions can be used with the present methods. Non PCR amplification methods include ligase chain reaction (LCR: Barany et al., *PCR Meth. Applic.*, 1:15-16 (1991)), self-sustained sequence replication (SSR: Muller et al., *Histochem. Cell Biol.*, 108:431-437 (1997)), also known as nucleic acid sequence-based amplification: NASBA) and its new derivative, cooperative amplification of templates by cross-hybridization (CATCH: Ehricht et al., *Eur. J Biochem.*, 243:358-364 (1997)), transcript-based amplification system (AMPLISCRIP[®], Kaylx Biosciences, Nepean, Ontario Canada), replicatable RNA reporter systems based on the Q beta replicase, hybridization-based formats such as strand-displacement amplification (SDA: Becton-Dickinson, Franklin Lakes, NJ; Walker et al. *Nucleic Acids Res.*, 20:1691-1696 (1992)), and chip-based microarrays such as Affymetrix GeneChip (Fodor et al., *Nature*, (Lond) 364:555-556 (1993)).

Signal amplification methods also can be used to enhance delectability such as with the use of compound probes (Fahrlander et al., *Bio/Technology*, 6:1165-1168 (1988)) or branched probes (Chiron Corp., Emeryville, CA; Urdea et al., *Nucleic Acids Symp. Ser.*, 24:197-200 (1991)) as is well known in the art.

Primer extension by PCR is performed by combining one or more primers with the target nucleic acid and a PCR buffer containing a suitable nucleic acid polymerase. The mixture is thermocycled for a number of cycles, which is typically predetermined, sufficient for the formation of a PCR reaction product, thereby enriching the sample to be assayed for the sequence of interest. Protocols for PCR are well known in the art (e.g., U.S. Pat. Nos. 4,683,192, 4,683,202, 4,800,159, and 4,965,188) and are available from a variety of sources (e.g., *PCR Technology: Principles and Applications for DNA Amplification*, H. Erlich, ed., Stockton Press, New York (1 989); and *PCR Protocols: A Guide to Methods and Applications*, Innis et al., eds., Academic Press, San Diego, CA (1 990)).

PCR is typically carried out by thermocycling, i.e., repeatedly increasing and decreasing the temperature of a PCR reaction admixture within a temperature range whose lower limit is about 30 degrees Celsius (30°C) to about 55°C, and whose upper limit is about 90°C to about 100°C. Increasing and decreasing the temperature can be continuous, but is preferably phasic with time periods of relative temperature stability at each of the temperatures favoring polynucleotide synthesis, denaturation and hybridization. Thus, the PCR mixture is heated to about 90-100°C for about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool to about 54°C, which is preferable for primer hybridization. The synthesis reaction may occur at room temperature up to a temperature above which the polymerase (inducing agent) no longer functions efficiently. Thus, for example, if Taq DNA polymerase is used as inducing agent, the temperature is generally about 70°C. The thermocycling is repeated until the desired amount of amplified product is produced.

A single frizzled gene-specific primer pair can be used in each amplification reaction. Alternatively, additional primers from other primers pairs can be included in the reaction. The primers are generally added in molar excess over template DNA. The conditions of the PCR are adjusted depending on a number of factors, including the degree of mismatch, the GC content of the primer, the length of the primer factors affecting PCR conditions, melting temperature of the primer, and product length and placement within the target sequence. Adjustments in the concentrations of the reaction components, especially magnesium concentration, can be used to enhance the conditions for PCR.

The PCR buffer contains the deoxyribonucleoside triphosphates (i.e., polynucleotide synthesis substrates) dATP, dCTP, dGTP, and dTTP and a polymerase, typically thermostable, all in amounts sufficient for the primer extension (i.e., polynucleotide synthesis) reaction. An exemplary PCR buffer comprises the following: 50 mM KCl; 10 mM Tris-HCl at pH 8.3; 1.5 mM MgCl₂; 0.001% (wt/vol) gelatin, 200 microMolar (μM) dATP, 200 μM dTTP, 200 μM dCTP, 200 μM dGTP, and 2.5 units

Thermus aquaticus (Taq) DNA polymerase I (U.S. Pat. No. 4,889,818) per 100 microliters (μ L) of buffer.

The inducing agent may be any compound or system which will function to accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, *E. coli* DNA polymerase I, Klenow fragment of *E. coli* DNA polymerase I, T4 DNA polymerase, other available DNA polymerases, reverse transcriptase, and other enzymes, such as heat-stable enzymes that facilitate combination of the nucleotides in the proper manner to form the primer extension products complementary to each nucleic acid strand. Generally, the synthesis will be initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths. There may be inducing agents, however, which initiate synthesis at the 5' end and proceed in the above direction, using the same process as described above. Frizzled gene-specific primers suitable for such inducing agents can be designed using the principles elaborated above for inducing agents that extend from the 3' end.

The PCR reaction can advantageously be used to incorporate into the product a preselected restriction site useful in later cloning and sequencing of the amplified product. This can be accomplished by synthesizing the primer with the restriction site in the 5' end of the primer.

3. Arrays

In cases where hybridization assays of multiple tumor cell genomes are desired to be performed simultaneously using the same intronic region-specific probes, it would be convenient to perform such hybridizations in an array format. Such assay formats and minaturizations thereof, i.e. microchip assays, are well known in the literature and could easily be adapted for the assays described herein. For example, see PCT WO 00/03037, which describes screening arrays of nucleotides using specific probes. After compilation of the sequences from a variety of tumor cells, these sequences can be used in a microarray

format on a microchip to perform simultaneous hybridization studies with various probes or sequences from other tumor cells.

Alternatively, such assay formats can be designed for use to study hybridization of an array of frizzled gene-specific sequences with a single tumor cell genome, or an array of the protein products derived from the translation of the frizzled gene sequences of a population of cells, or an array of antibodies to such protein products, or combinations thereof in two-dimensional arrays. Such microarray hybridization assays can easily be performed using a variety of known microchip assay formats and techniques.

In addition to such arrays, the methods of the present invention can be adapted to an array format to screen small molecule libraries for their ability to modulate the biological activities of metastatic cells. For example, small molecule libraries can be screened as potential ligands for frizzled receptors in an array using the antibodies described herein that bind to the extracellular domains in a competitive (or other) assay format. Small molecules which compete with the antibodies for binding to the frizzled receptor would be candidates for further screening as therapeutic agents, and may include small peptide fragments, nucleic acids or organic compound, or combinations thereof.

Analysis of nucleic acid from known tumor cells or products produced therefrom by primer extension as described herein also can include analysis of the sequence of the amplified frizzled gene of the tumor cell DNA. For example, amplified products such as from a PCR can be directly cloned by a variety of methods well known in the art (e.g., Ausubel et al., *Molecular cloning of PCR products*, in: Short Protocols in Molecular Biology, 3rd Ed. John Wiley & Sons, Inc., New York, pp. 15-32 (1997)). Cloning of amplified products can be accomplished using "sticky ends" such as the TA cloning method or by "blunt end" cloning approaches. Alternatively, frizzled gene-specific primers can be designed with endonuclease restriction sites at the 5' end of the primer which are designed for cutting and insertion into a specified cloning vector. Kits are commercially available for cloning amplified products such as produced in a PCR (e.g., Invitrogen, Inc., San Diego, CA).

Methods for sequencing genes are well known, including the Sanger dideoxy mediated chain-termination approach and the Maxam-Gilbert chemical degradation approach. These and other nucleic acid sequencing methods are described, for example, in Sambrook et al., *supra*, (1989) (chapter 13). Nucleic acid sequencing can be automated
5 using a number of commercially available instruments.

Amplified products also can be directly sequenced without cloning the product (e.g., Sambrook et al., *supra*, (1989) (14.22-14.29)). Amplified products that have been purified, for example, by gel electrophoresis, are suitable for direct sequencing (*id.*).

4. Antibodies

10 The present invention relies on the ability to design antigen-antibody binding pairs using the extracellular domains of the frizzled receptor as the antigenic epitope. Such antibodies are useful for detecting tumor-specific frizzled receptor epitopes, as well as for immunotherapy of cancers. Although many regions of the extracellular domain may have sufficient size and tertiary structure to be independently antigenic, others may require
15 coupling to T helper epitopes. This can be achieved using techniques that are well known in the art (e.g., Harlow and Lane, "Antibodies: A laboratory Manual," Cold Spring Harbor Laboratory Press (1988)). Although there are numerous T helper epitopes known in the art, tetanus toxin and measles virus fusion (MVF) protein T helper epitopes are exemplary. As used herein, the term "frizzled epitope" refers both to an independently antigenic
20 extracellular domain of a frizzled receptor, as well as one which is coupled to a T helper epitope to enhance immunogenicity.

An anti-frizzled epitope antibody ("anti-Fz Ab") is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as polypeptide fragments of antibodies that retain a specific binding affinity for its target antigen of, e.g., at least about
25 $1 \times 10^5 \text{ M}^{-1}$. One skilled in the art would know that antibody fragments such as Fab, $F(ab')_2$ and Fv fragments can retain specific binding activity for their target antigen and, thus, are included within the definition of an antibody herein. In addition, the term "antibody" as used herein includes naturally occurring antibodies as well as non-naturally occurring

antibodies such as domain-deleted antibodies (Morrison et al., WO 89/07142) or single chain Fv (Ladner et al., U.S. Pat. No. 5,250,203). Such non-naturally occurring antibodies can be constructed using solid phase peptide synthesis, can be produced recombinantly or can be obtained, for example, by screening combinatorial libraries consisting of variable
5 heavy chains and variable light chains using known methods, such as those described by Huse et al., *Science*, 246:1275-1281 (1989).

Antibodies to frizzled epitopes can be prepared using a substantially purified extracellular region of a frizzled receptor, or a fragment thereof, which can be obtained from natural sources or produced by recombinant DNA methods or chemical synthesis.

10 For example, recombinant DNA methods can be used to express the frizzled gene sequence alone or as a fusion protein, the latter facilitating purification of the antigen and enhancing its immunogenicity.

Antisera containing polyclonal antibodies reactive with antigenic epitopes of the frizzled receptor can be raised in rabbits, goats or other animals. The resulting antiserum
15 can be processed by purification of an IgG antibody fraction using protein A-Sepharose chromatography and, if desired, can be further purified by affinity chromatography using, for example, Sepharose conjugated with a peptide antigen. The ability of polyclonal antibodies to specifically bind to a given molecule can be manipulated, for example, by dilution or by adsorption to remove crossreacting antibodies to a non-target molecule.
20 Methods to manipulate the specificity of polyclonal antibodies are well known to those in the art (e.g., Harlow and Lane, *supra*, (1988)).

A monoclonal antibody specific for the frizzled epitope can be produced using known methods (Harlow and Lane, *supra*, (1988)). Essentially, spleen cells from a mouse or rat immunized as discussed above are fused to an appropriate myeloma cell line such as
25 SP2/0 myeloma cells to produce hybridoma cells. Cloned hybridoma cell lines can be screened using a labeled frizzled epitope to identify clones that secrete an appropriate monoclonal antibody. A hybridoma that expresses an antibody having a desirable specificity and affinity can be isolated and utilized as a continuous source of monoclonal

antibodies. Methods for identifying an anti-Fz Ab having an appropriate specificity and affinity and, therefore, useful in the invention are known in the art and include, for example, enzyme-linked immunoadsorbence assays, radioimmunoassays, precipitin assays and immunohistochemical analyses (e.g., Harlow and Lane, *supra*, (1988) (chapter 14)).

5 An anti-Fz Ab can be characterized by its ability to bind specifically to the cells that express the particular frizzled receptor. In addition, an anti-Fz Ab of the invention can be used to purify frizzled receptors from a biological or experimentally prepared sample. For example, such antibodies can be attached to a solid substrate such as a resin and can be used to affinity purify the frizzled receptor. In addition, the anti-Fz Ab can be used to
10 identify the presence of the frizzled receptor in a sample. In this case, the antibody can be labeled with a detectable label such as a radioisotope, an enzyme, a fluorochrome or biotin. An anti-Fz Ab can be delectably labeled using methods well known in the art (e.g., Harlow and Lane, *supra*, (1988) (chapter 9)). Following contact of a labeled anti-Fz Ab with a sample, specifically bound labeled antibody can be identified by detecting the label.

15 5. Immunoassays

The binding of an anti-Fz Ab to the frizzled receptor also can be determined using immunological binding reagents. As used herein, an immunological binding reagent includes any type of biomolecule that is useful to detect an antibody molecule. An
20 immunological binding reagent can include a labeled second antibody. A second antibody generally will be specific for the particular class of the first antibody. For example, if an anti-frizzled epitope antibody (i.e., a first antibody) is of the IgG class, a second antibody will be an anti-IgG antibody. Such second antibodies are readily available from commercial sources. The second antibody can be labeled using a detectable moiety as
25 described above. When a sample is labeled using a second antibody, the sample is first contacted with a first antibody (i.e., anti-Fz Ab), then the sample is contacted with the labeled second antibody, which specifically binds to the first antibody and results in a labeled sample. Alternatively, a labeled second antibody can be one that reacts with a

chemical moiety, for example biotin or a hapten that has been conjugated to the first antibody (e.g., Harlow and Lane, *supra*, (1988) (chapter 9)). Immunological binding agents also can include avidin or streptavidin when the anti-frizzled epitope antibody is labeled with biotin.

5 Principally, all conventional immunoassays are suitable for the detection of frizzled receptors. Direct binding as discussed above or competitive tests can be used. In a competitive test, the anti-Fz Ab can be incubated with a sample and with the frizzled receptors or a fragment thereof (produced as described herein) both simultaneously or sequentially. The frizzled receptors from the sample preferably competes with the added
10 frizzled epitope (hapten) of the invention for the binding to the antibody, so that the binding of the antibody to the hapten in accordance with the invention is a measure for the quantity of antigen contained in the sample. In a heterogeneous competitive immunoassay where the liquid phase is separated from the solid phase, both the antibody or the peptide can be labeled or bound to a solid phase. The exact amount of antigen contained in the sample can
15 then be determined in a conventional manner by comparison with a standard treated in the same manner.

 All competitive test formats that are known to the expert can be used for the detection. The detection can be carried out, for example, using the turbidimetric inhibition immunoassay (TINIA) or a latex particle immunoassay (LPIA). When a TINIA is used, the
20 peptide or peptide derivative of the invention is bound to a carrier such as dextran (EP-A-0 545 350). This polyhapten competes with the analyte contained in the sample for the binding to the antibody. The formed complex can be determined either turbidimetrically or nephelometrically. When an LPIA is employed, particles, preferably latex particles, are coated with the peptides of the invention and mixed with the antibody of the invention and
25 the sample. When an analyte is present in the sample, agglutination is reduced.

 Enzyme immunoassays (Wisdom, *Clin. Chem.*, 22(8):1243-1255 (1976), and Oellerich, *J Clin. Chem. Clin. Biochem.*, 18:197-208 (1980)), fluorescence polarization immunoassays (FPIA) (Dandliker et al., *J Exp. Med.*, 122:1029 (1965)), enzyme-

multiplied immunoassay technology (EMIT) (Rubenstein, *Biochem. Biophys. Res. Comm.*, 47:846-851 (1972)) or the CEDIA technology (Henderson et al., *Clin. Chem.*, 32:1637-41 (1986)) also are suitable immunological based assays for detection of frizzled receptors.

5 6. Immunotherapeutics

One aspect of the present invention is the design of immunotherapies for cancer. Wnt signaling through frizzled receptors has been described to inhibit apoptosis. Also, some of the genes that are regulated by TCF/beta-catenin are known to be associated with the cell cycle and cell proliferation. By blocking the binding of Wnt proteins to their
10 receptors via antibodies directed to the extracellular portion of frizzled receptors, this pathway can be interrupted. Thus, it is believed that disruption of the downstream translocation of beta-catenin to the nucleus results in slower tumor growth or death of the cell.

As used herein, the term "modulating a biological activity of a malignant cell"
15 refers to the ability of the antibody to effect cellular function. These effects may manifest themselves as cell growth inhibition, the ability to elicit a cytotoxic response to the malignant cell, or other such negative effects on the malignancy. Although not wishing to be bound to any particular theory, it is believed that this effect is caused by the antibody binding to the extracellular domain of the frizzled receptor in a way that interferes with the
20 Wnt/frizzled signalling pathway.

The pharmaceutical compositions of the present invention include therapeutically effective amount of the appropriate anti-Fz Ab in a pharmaceutically acceptable carrier. Such carriers are well known in the art. Examples of appropriate carriers are those that are known for delivery of interferons, such as normal saline, dextrose, etc. The mode of
25 administration of the pharmaceutical composition necessarily depends on the type and location of the target tumor cells. Accordingly, the compositions can be delivered, e.g., parenterally, or typically intravenously in a solution, suspension or emulsion.

Pharmaceutical compositions and routes of administration of aqueous compositions comprise an effective amount of the antibody in the pharmaceutically acceptable carrier. By "pharmaceutically acceptable" it is intended that the compositions do not produce adverse, allergic reactions when administered to the animal or human subject, and such carriers include solvents, dispersion media, coatings and the like. Excipients may also be added, which include, *inter alia*, antimicrobial agents, isotonicity enhancers, absorption delaying agents, surfactants, dispersants, preservatives, and the like.

For administration to an animal or human subject, the solutions are necessarily prepared to meet all FDA Office of Biologics standards. As such, they are normally dialyzed to remove undesired small molecular weight molecules or lyophilized with other active and excipient ingredients for reconstitution prior to administration. As would be appreciated by one of skill in the art, the administration parameters, such as dosage and timing, will necessarily depend on the type and location of the metastases to be treated and would easily be determined using routine optimization principles based on other like immunotherapeutics. Routes of suitable administration may include injection, intravenous, intramuscular, subcutaneous, intralesional, and the like. Alternatively, the immunotherapeutics of the present invention can be formulated for other local routes of administration as topicals, inhalants, orthotopic, ophthalmic, and the like.

An "effective" amount of the immunotherapeutics of the present invention is, of course, determined based on the intended therapeutic goal. As such, a "dosage" of the therapeutic refers to the unit amount of the therapeutic expected to achieve the desired goal, each unit containing a predetermined quantity of the therapeutic to be administered by the appropriate route of administration. Administration may also be spaced out over time to maximize the therapeutic effect, such as two to six administrations spaced out in intervals of several hours to several weeks.

The course of treatment may be monitored using appropriate immunoassays. For example, the level of circulating anti-Fz Abs following administration can easily be

monitored using labeled anti-immunoglobulin antibodies in any of a number of commercially available assay formats.

EXAMPLES

The following examples are included for illustrative purposes only and are not intended to limit the scope of the invention.

Example 1

Expression of frizzled gene mRNA from normal and cancer cells

To evaluate frizzled receptors for their potential as tumor associated antigens, the mRNA from various hematologic and epithelial tumors were screened, as well as the mRNA from normal cell lines. In this example total RNA was extracted from HNSCC lines (PCI13, Detroit 562, RPMI 2650, SNU1076, KB, AMC4), a CLL line (Lesch), a Burkitt lymphoma line (Ramos), glioma lines (U87MG, and U373MG), normal human bronchial epithelial cell lines (Clonetics, San Diego, CA) and normal oral squamous epithelial (OSE) cells using Trizol® (Gibco, BRL, Grand Island, New York). Reverse transcription was performed using 1 µg of RNA from each sample and the Superscript™ Preamplification kit (Gibco BRL). Different pairs of gene-specific primers based on sequences of cloned human isoforms of the frizzled genes were used for reverse transcriptase-PCR (RT-PCR) analysis.

The following list summarizes the primer pairs used:

FZD2 (Seq. ID 21): 5'-cagcgtcttgcccgaccagatcca-3'(reverse);

(Seq. ID 22) 5'-ctagcgccgctcttcgtgtacctg-3' (forward).

FZD5: (Seq. ID 23) 5'-ttcatgtgcctggtggtgggc-3' (forward);

(Seq. ID 24) 5'-tacacgtgcgacaggacacc-3' (reverse)

G3PDH: (Seq. ID 25) 5'-accacagtccatgccatcac-3' (forward);

(Seq. ID 26) 5'-tacagcaacagggtggtgga-3' (reverse).

Frizzled 2 was amplified with 25 cycles of PCR. Frizzled 5 and G3PDH were amplified with 30 cycles of PCR. The amplification products for frizzled 2 and G3PDH are shown. The expression of the frizzled isoforms in cancer cells was confirmed by sequencing.

5 In an expanded cell set total RNA was extracted from 14 tumor cell lines, two normal human bronchial epithelial cell lines and IO normal oral mucosal epithelial cells by using Trizol®. Cancer cell lines consisted of 10 head and neck squamous cell cancers (HNSCC), 2 B-cell tumor cell lines, and 2 glioma cell lines. Two normal human bronchial epithelial cell samples were purchased from Clonetics (San Diego, CA). Ten normal oral
10 mucosal cell samples (Oral SC) were obtained from scraping the oral mucosa from 10 volunteers. RT-PCR analysis was performed as described above. These results are shown in Table III below.

Table III

: Summary of frizzled genes detected by RT-PCR in normal and cancer cells

mRNA amplified	Normal (11)		Cancer (14)		
	Oral SC (10)	NHBE (2)	Glioma (2)	HNSCC (10)	B cell tumor (2)
Frizzled 2	0	1	2	10	2
Frizzled 5	4	1	1	9	1

As shown, in some instances, the frizzled gene associated mRNA is expressed in
5 overabundance in cancer cells when compared to normal cells.

Example 2

Analysis of frizzled 2 protein expression in cancer vs. normal cells

To determine the amount of protein expressed in the cells studied in Example 1,
adherent cells in culture were harvested and lysed with a solution containing 25 mM Tris
10 HCl, 150 mM KCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholic acid, 0.1%
sodium dodecyl sulfate, 1mM NaVO₃, 1 mM NaF, 20 mM α -glycerophosphate and
protease inhibitors. Twenty μ g of protein from each cell line was separated by SDS-PAGE
and transferred to a PVDF membrane. The membrane was immersed in 2% I-block, 0.05%
Tween X in PBS and then incubated with a 1:500 dilution of polyclonal goat anti-human
15 frizzled 2 IgG (Santa Cruz Biotechnology, Santa Cruz, CA). These primary antibodies
were then detected by horseradish peroxidase-conjugated donkey anti-goat IgG (Santa
Cruz) and chemiluminiscence (ECL detection reagents, Amersham Life Science,
Aylesbury, UK). To verify relative amount of protein transferred in each lane, the presence
of actin was measured with an actin monoclonal antibody (Chemicon International Inc,
20 Temecula, CA).

The result of this experiment (not shown) revealed that, although frizzled 2
associated mRNA was detected by RT-PCR as shown in Table III, no detectable amount of
protein was detectable immunologically. These contrasting results indicate that tumor

specificity of the frizzled receptors at the protein level cannot accurately be predicted by looking at tumor specificity at the mRNA level.

Example 3

The effects of anti-Fz Abs on cancer cell growth

5 The ability to block the Wnt-frizzled signaling pathway can provide an effective way of limiting growth of tumor cells. In order to determine the efficacy of using such anti-Fz Abs as an adjunctive passive immunotherapy, such as that observed using humanized anti-HER2 antibodies (Herceptin, Genentech, inc., South San Francisco, California), the effects of anti-frizzled 2 antibodies on the growth of HNSCC cells was
10 studied. Soluble inhibitors of frizzled receptors have been described to induce apoptosis secondary to their inhibition of frizzled signaling. Accordingly, this experiment was designed to test the efficacy of anti-Fz Abs to perform the same function.

 Cell proliferation was determined by a calorimetric MTT-based assay. Briefly, either 7.5×10^3 or 10×10^3 SNU1076 cells per well were cultured in a 96 well plate. After
15 24 hours, graded amounts of polyclonal goat anti-human frizzled-2 antibody containing 300 ng, 30 ng, 3 ng, and 0.3 ng were added in the culture medium. The same concentrations of goat serum or Goat antihuman IgG (Fisher Scientific, Pittsburgh, PA) were used as an isotype control. On 1, 2, 3, or 4 days after incubating antibody, 20 μ l of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-based solution was added to the
20 wells for four hours prior to lysis with 15% SDS, 0.015 M HCl. Absorbances at 570 and 650 nm were measured. The results are depicted in Figure 4 and also given in Table IV below. Data represent the normalized growth fraction of the specific antibody treated cells to that of the control antibody treated cells (in triplicate).

Table IV

Cell proliferation in presence of anti-Fz Ab

FZD	300mg	30 ng	3 ng	0.3 ng
Day 1	87.88±9.04	99.21±9.07	108.68±14.58	112.65±13.50
Day 2	68.50±8.50	86.08±10.80	90.33±6.67	89.18±7.97
Day 3	65.09±9.26	86.03±5.74	75.14±19.08	90.22±2.64
Day 4	53.82±4.20	64.52±7.41	88.19±10.97	81.37±7.07
Day 5	53.75±4.57	81.27±9.04	92.98±8.81	90.84±5.71

As shown, treatment with antibodies markedly decreases the proliferation of
 5 SNU1076 cells. In a control experiment (results not shown), there was not appreciable
 effect of the same antibody on the growth of normal cells.

Example 4

The effects of anti-Fz Abs on cancer cell apoptosis

The effects of the anti-Fz Abs from Example 3 on apoptosis of SNU1076 cells was
 10 also studied. Cells were grown in RPMI-1640 supplemented with 10% FBS. The cells
 were treated for 72 hours with 300 ng/ml anti-Fz Ab, or control polyclonal antibodies.
 Two assays were used to quantify the cytotoxic effect of the antibodies as follows:

As shown in Figure 5, cells were detached from the flasks by trypsin treatment and
 incubated for 10 minutes in growing medium with 5 µg/ml Propidium iodide and 40 nM
 15 DiOC₆ and analyzed by flow cytometry. Viable cells (Alive, right bars) had high DiOC₆
 (FL-1) and low PI (FL-3) fluorescence, while apoptotic cells (left bars) had low DiOC₆ (FL-
 1) and low PI (FL-3) fluorescence.

As shown in Figure 6, cells were detached from the flasks by trypsin treatment and
 incubated overnight in a hypotonic buffer (0.1% citrate, 0.1% SDS) containing 50 µg/ml PI
 20 and 100 µg/ml RNase. The amount of DNA was then measured by flow cytometry, and
 apoptotic cells were defined as having a DNA content lower than the G₀G₁ levels (sub-G₀
 cells).

Example 5

Identification of tumor-specific frizzled epitopes

As described above in Examples 1 to 4, frizzled 2 antigens may be differentially, overexpressed in cells of malignant phenotype, whereas many frizzled gene products may be expressed in normal and abnormal cells. Whereas the frizzled 2 systems is exemplary herein, it is readily apparent that tumor specific frizzled antigens from the other frizzled genes are equally attractive targets for cancer immunotherapies. Accordingly, the methods taught herein can easily be adapted to other frizzled genes and their protein products.

For example, a panel of tumor cells that can be screened are derived from the panel of 60 lines which are being characterized in the NIH Developmental Therapeutics Program. The cell lines that are currently available in the lab include: (non-small cell lung cancer) A549/ATCC, NCI-H226, NCI-H460, HOP-62, HOP-92, (colon cancer) HT29, HCT-116, (breast cancer) MCF7, NCI/ADR-RES, MDA-MB-231/ATCC, T-47D, (ovarian cancer) OVCAR-3, OVCAR-4, SK-OV-3, (leukemia) CCRF-CEM, K-562, MOLT-4, HL-60(TB), RPMI-8226, (renal cell) 786-0, TK-10, (prostate cancer) PC-3, DU-145. Normal control cell lines will be purchased as previously from Clonetics.

The expression of frizzled proteins can be confirmed with commercially available antibodies to frizzled isoforms, or where none are available, they can easily be prepared using known methods.

The overall strategy is to use the least conserved region of the frizzled protein, attempting to preserve the most native structure possible and to generate the most potent immune response. The most versatile method for designing vaccines of defined regions is naked plasmid DNA. The advantages are that the vectors can be rapidly redesigned to change the length of sequence that is expressed, discontinuous regions of the protein can be co-expressed, and the DNA sequence of the protein can be fused to other epitopes to enhance antigenicity. It affords the versatility of expressing soluble, membrane bound

proteins, or small peptide fragments. Also gene transfer by this technique is a powerful tool to introduce multiple protein elements into the same or separate locations. In this system single or multiple proteins can be locally expressed. Injecting a combination of plasmids expressing antigens and costimulators like B7.1 and B7.2 results in enhanced
5 immune responses.

Several plasmids have been constructed which are under the control of the cytomegalovirus (CMV) promoter which has been found to enable high levels of antigen expression in injected muscle. The pCMVint vector includes the cytomegalovirus (CMV) E I promoter, the simian virus (SV40) t-intron, and the SV-40 polyadenylation site. The
10 ACB vector has the same elements except the polyadenylation sequence is from the bovine growth hormone gene. For example, a preferred plasmid construct for frizzled-2 encodes the least homologous region of the frizzled gene between the ninth and tenth cysteine. These cysteines stabilize a configuration that enables antibody binding to the native protein. This polypeptide fragment is fused at the amino terminus or the carboxylterminus
15 via a short linker to a tetanus toxin or measles MVF T helper epitope (see below). These minigenes are constructed with overlapping oligonucleotides. The oligonucleotides are 5' prime phosphorylated with T4 kinase (Boehringer Mannheim, Indianapolis, IN) at room temperature for 30 minutes, annealed by boiling an equimolar admixture of two complementary oligomers and slow cooling. The double stranded oligonucleotides are then
20 ligated 3' to the tissue plasminogen leader (TPA) leader into the EcoR47III site in frame and into the BamHI site of the pBluescript SKII vector. The minigene is then subcloned into the pCMV and pACB vectors between the PstI and XbaI sites as previously described.

The inserts for the vectors are designed as described above. The frizzled putative B cell epitope is from the published sequence. The tetanus toxin and measles MVF T helper
25 epitopes have been optimized for human codon usage by the most frequently used codon per amino acid. The DNA constructs have an initiating methionine and stop codons added to the 5' and 3' ends respectively. The amino acid and DNA sequences are summarized

below with the short GPSL linker sequence in bold and the T cell helper epitope underlined.

Tetanus toxin epitope fused to a frizzled domain

5

pFZD2-IT

Seq. ID 27:

MCVGQNHSEDCAPALLTTAPPPGLQPGAGGTPGGPGGGGAPPRYATLEBPF
HC -**GPSL-VDDALINSTKIYSYFPSV**-STOP

10

Seq. ID 28:

ATG TGC GTC GGC CAG AAC CAC TCC GAG GAC GGA GCT CCC GCG CTA CTC
ACC ACC GCG CCG CCG CCG GGA CTG CAG CCG GGT GCC GGG GGC ACC
CCG GGT GGC CCG GGC GGC GGC GGC GCT CCC CCG CGC TAC GCC ACG CTG
15 **GAG CAC CCC TTC CAC TGC-GGC CCC AGC CTG- GTG GAC GAC GCC CTG**
ATC AAC AGC ACC AAG ATC TAC AGC TAC TTT CCC AGC GTG TAG

pTT-FZD2

Seq. ID 29:

20 **MVDDALINSTKIYSYFPSV-GPSL-**
CVGQNHSEDCAPALLTTAPPPGLQPGAGGTPGGPGGGGAPPRYATLEHPFHC-
STOP

Seq. ID 30:

25 **ATG GTG GAC GAC GCC CTG ATC AAC AGC ACC AAG ATC TAC AGC TAC TTT**
CCC AGC GTG-GGC CCC AGC CTG-TGC GTC GGC CAG AAC CAC TCC GAG
GAC GGA GCT CCC GCG CTA CTC ACC ACC GCG CCG CCG CCG GGA CTG CAG

CCG GGT GCC GGG GGC ACC CCG GGT GGC CCG GGC GGC GGC GGC GCT
 CCC CCG CGC TAC GCC ACG CTG GAG CAC CCC TTC CAC TGC TAG

Measles MVG epitope fused to a frizzled domain

5 PFZD2-MMVF

Seq. ID 31:

MCVGQNHSEDGAPALLTTAPPPGLQPGAGGTPGGPGGGGAPPRYATLEHPFHC-
 GPSL-KLLSLIKGVIVHRLEGVE-STOP

10 Seq. ID 32:

ATG TGC GTC GGC CAG AAC CAC TCC GAG GAC GGA GCT CCC GCG CTA CTC
 ACC ACC GCG CCG CCG CCG GGA CTG CAG CCG GGT GCC GGG GGC ACC
 CCG GGT GGC CCG GGC GGC GGC GGC GCT CCC CCG CGC TAC GCC ACG CTG
 GAG CAC CCC TTC CAC TGC-GGC CCC AGC CTG- AAG CTG CTG AGC CTG

15 ATC AAG GGC GTG ATC GTG CAC CGC CTG GAG GGC GTG GAG TAG

PMMVF-FZD2

Seq. ID 33:

MKLLSLIKGVIVHRLEGVE-GPSL-

20 CVGQNHSEDGAPALLTTAPPPGLQPGAGGTPGGPGGGGAPPPYATLEHPFHC-
 STOP

Seq. ID 34:

ATG AAG CTG CTG AGC CTG ATC AAG GGC GTG ATC GTG CAC CGC CTG GAG
 25 GGC GTG GAG-GGC CCC AGC CTG-TGC GTC GGC CAG AAC CAC TCC GAG
 GAC GGA GCT CCC GCG CTA CTC ACC ACC GCG CCG CCG CCG GGA CTG CAG
 CCG GGT GCC GGG GGC ACC CCG GGT GGC CCG GGC GGC GGC GGC GCT
 CCC CCG CGC TAC GCC ACG CTG GAG CAC CCC TTC CAC TGC TAG

Plasmid DNA is prepared using Qiagen Maxiprep (Chatsworth, CA) kits with the modification of adding one tenth volume 10% Triton X- 1 14 (Sigma, St. Louis, MO) to the clarified bacterial lysate prior to applying it to a column. Prior to injection the residual
 5 endotoxin level is quantified using a limulus extract clot assay (Associates of Cape Cod, Woods Hole, MA). A level of ≤ 5 ng endotoxin/ μ g DNA need be obtained prior to use in an animal. The DNA is resuspended in a sterile pyrogen free saline solution for injection.

Twenty-eight female mice are divided into groups of 4 mice each. They are injected in the dermis of the tail with a combination of 50 μ g plasmid encoding a
 10 costimulator and 50 μ g linker plasmid diluted in normal saline at weeks zero, one and two. A group with empty vector is included as a negative control. The groups are as follows:

Table V

Vector groups for expression of frizzled-2-receptors

Group	Plasmid 1	Plasmid 2
A	pTT-FZD2	nCMV
B	pTT-FZD2	nCMVB7-1
C	pTT-FZD2	nCMVB7-2
20 D	pFZD2-TT	nCMV
E	pFZD2-TT	nCMVB7-1
F	pFZD2-TT	nCMVB7-2
G	-----	nCMV

25 Another group of mice in similar groups is immunized using the pMMVF-FZD2 and pFZD2-MMVF set of linked epitope plasmids.). The nCMVB7-1 and nCN4VB7-2 constructs encode the cDNAs for murine CD80 and CD86 (provided by G. Freeman (Dana-Farber Cancer Institute, Boston, MA).

Mice are bled prior to the start of the experiment and then every two weeks thereafter. Serum is separated and stored at -20°C prior to testing. On week ten (seven weeks after the last injection) mice are sacrificed. The titers of antibody are tested by anti-peptide ELISA. Ninety-six well plates (Costar) are coated with 50 ul/ well 20 µ/ml peptide in phosphate buffered saline (PBS) overnight at 4°C. The plates are then washed and blocked with 200 ul/ well 2% bovine serum albumin (BSA) in PBS. Sera are diluted in 2% BSA in PBS. After overnight incubation at 4°C the plates are washed. Bound murine IgG is detected by alkaline phosphatase conjugated-goat anti-murine IgG (Jackson Immunoresearch Laboratories) followed by p-nitrophenylphosphate substrate. The titration curves for each sera are compared using DeltaSOFT II v. 3.66 (Biometallics, Princeton, NJ).

Mice that develop sufficiently high titers of antibody that bind to the peptide are tested for specificity to frizzled 2 by fluorescent cytometry with cells that express the protein by transfection and known tumor cells that have the mRNA. Binding is tested by Western blot analysis of cells that express this isoform and to cells that have been found to express other frizzled family members.

If the antibody response is weak then the vectors can be redesigned with other known potent T helper epitopes. In addition, other vectors can be designed where the frizzled protein fragment is altered to achieve the most desirable conformation. Another immunization strategy will be to use a prime boost method. The animals are originally injected with plasmid DNA and then are boosted with peptide or recombinant protein in incomplete Freund's adjuvant.

Once antibodies have been identified that delay cancer cell growth in cell culture the ability of these antibodies can be tested for potential *in vivo* efficacy in Mice. For example, the H-2^b thymoma line EL4 can be used as a syngeneic tumor in C57Bl/6 mice. This line is transfected with a human frizzled expression vector and selected in neomycin. The expression vector is made by excising the frizzled containing insert from a pET3a bacterial expression vector with NdeI and BamHI and ligating the insert into pcDNA3

which has a CMV promoter and a neomycin selection cassette. Thirty two female C57B1/6 mice are divided into groups of 8 mice each. They are injected in the dermis of the tail with a combination of 50 μ g plasmid encoding a costimulator and 50 μ g linker plasmid diluted in normal saline at weeks zero, one and two. A group with empty vector is included as a negative control. On day 28 the mice are injected with 20×10^6 frizzled transfected EL4 cells or untransfected cells. The mice are monitored three times a week for weight, and tumor growth measured with a caliper. Tumor volume is calculated by $\text{length} \times \text{width}^2 \times \pi/6$. Mice are sacrificed four weeks post tumor challenge or if the tumor burden reaches approximately 2000mm^3 . Inhibition of tumor growth is determined by ANOVA.

Polyclonal antibodies may have low levels of cross reactivity with other proteins that are below the detection level of the binding assays but convey a biologic effect. The antibodies may have not only a blocking or a steric effect, but may also be able to cross link the receptor and make it constitutively active. The presence of the effector antibody may be a minor population in the polyclonal sera and the effect may appear insignificant. Whereas a monoclonal would have a pure population and only one effect. However the assay using polyclonal antibodies will determine if the frizzled expressing cell lines are susceptible to antiproliferative activity in the pool of anti-frizzled IgG. This provides useful information with respect to the methods that are useful for screening panels of monoclonal antibodies.

The examples set forth above are provided to give those of ordinary skill in the art with a complete disclosure and description of how to make and use the preferred embodiments of the compositions, and are not intended to limit the scope of what the inventors regard as their invention. Modifications of the above-described modes for carrying out the invention that are obvious to persons of skill in the art are intended to be within the scope of the following claims. All publications, patents, and patent applications cited in this specification are incorporated herein by reference as if each such publication, patent or patent application were specifically and individually indicated to be incorporated herein by reference.

Claims

We claim:

1. A purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell.

2. The purified antibody of claim 1, wherein the extracellular domain comprises an amino terminal peptide fragment of the frizzled receptor.

3. The purified antibody of claim 1 further comprising an antibody fragment having an antigen binding region that specifically binds to the epitope.

4. The purified antibody of claim 1, wherein the antibody is capable of sensitizing malignant cells expressing the frizzled receptor to a cytotoxic factor.

5. The purified antibody of claim 1, wherein the antibody inhibits binding of a Wnt ligand to the frizzled receptor.

6. The purified antibody of claim 1 further comprising a detectable label.

7. The purified antibody of claim 1, wherein the antibody is a human antibody.

8. The purified antibody of claim 1, wherein the antibody is a monoclonal antibody.

9. The purified antibody of claim 1, wherein the antibody binds to a frizzled-2 receptor amino terminal extracellular domain.

10. The purified antibody of claim 1, wherein the frizzled receptor amino terminal extracellular domain has a sequence that is greater than 80% homologous to an amino acid sequence selected from the group Seq. ID. No.s 61, 63, 64, 66, 68, 69, 71, 73, 75 and 77.

11. An isolated nucleic acid, comprising at least one nucleotide fragment encoding a peptide having an amino acid sequence that is greater than 80% homologous to an amino acid sequence selected from the group Seq. ID No.s 61, 63, 64, 66, 68, 69, 71, 73, 75 and 77.

5 12. The isolated nucleic acid of claim 11, further comprising at least one nucleotide fragment encoding a T cell epitope.

13. A transgenic non-human animal, comprising at least one isolated nucleic acid of claim 11.

10 14. A recombinant vector, comprising at least one nucleic acid according to claim 11 functionally attached to a promoter region upstream of the nucleic acid.

15. A host cell comprising at least one recombinant vector according to claim 14.

15 16. A pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.

20 17. A method for modulating a biological activity of a malignant cell that expresses a frizzled receptor comprising administering a pharmaceutical composition comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell, in a pharmaceutically acceptable carrier.

25 18. A frizzled receptor epitope conjugate comprising at least one epitope in an extracellular domain of the frizzle receptor expressed on a malignant cell and at least one epitope specific to a T cell antigen.

19. The conjugate of claim 18, wherein the T cell antigen is also an epitope in an extracellular domain of the frizzle receptor expressed on a malignant cell

20. The conjugate of claim 18 further comprising a linker moiety.

21. The conjugate of claim 20, wherein the linker is GPSL.

5 22. A pharmaceutical composition useful as a vaccine against malignancy for administration to a patient having a predisposition for the malignancy, comprising a purified antibody for modulating a biological activity of a malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell.

10 23. A method of immunizing a subject against a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:

a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant
15 cell; and

b) administering the antibody in a pharmaceutically acceptable carrier in an amount sufficient to inhibit the malignancy.

24. A method of treating a subject with a malignancy comprised of malignant cells that express a frizzled receptor, said method comprising the steps of:

20 a) identifying an antibody for modulating a biological activity of the malignant cell that expresses a frizzled receptor, wherein said antibody specifically binds to at least one epitope in an extracellular domain of the frizzle receptor expressed on the malignant cell; and

b) administering the antibody in a pharmaceutically acceptable carrier in an
25 amount sufficient to modulate a biological activity of the malignant cell.

25. An assay for identifying a frizzled receptor expressed by a malignant cell, wherein said frizzled receptor comprises at least one epitope in an extracellular domain, comprising the steps of:

- a) identifying an antibody that specifically binds to the epitope;
- 5 b) exposing a sample of cells suspected of expressing the frizzled receptor to the antibody; and
- c) determining the extent of binding of the antibody to the cells.

26. A screening assay for identification of small molecules that modulate frizzled receptor activity, comprising:

- 10 a) selecting a library of the small molecules comprising a plurality of different chemical structures;
- b) contacting the small molecules with an extracellular domain of a frizzled receptor which is capable of binding to its corresponding Wnt protein; and
- c) measuring binding of a ligand to the frizzled receptor in the presence of the
- 15 small molecule, wherein the ligand is selected from the group consisting of the small molecule, the Wnt protein, and an antibody to the extracellular domain of the frizzled receptor.

1/16




FIG. 1

2/16

Alignment of several frizzled family members

→ amino terminal domain

fz3/mouse	-----MAVSWIVFDLWLLTVFLG---QIGGHS-----LFSCE
fz4/mouse	-----MAWPGTGPS---SRGAPGGVGLRLGLLLQFLLLLRPTLGFGD-----EEERRCD
fz8/mouse	-----MEWGYL-----LEVTSLLAALAVLQRSSG-AAAASAK-----ELACQ
fz5/human	-----MARPD-----SAPPSLL---LLLLAQLVG-RAAAASK-----APVCQ
fzd9/human	-----MAVAPLRGALLLWQLLAAGGALEIGRFD-----PERGRG-----AAPCQ
fz1/rat	LEAPLLLGVRAPAG---QVSG-PGQORPPPPQPOQGG---QQYNGERG---ISIPDHGYCQ
fz2/rat	-----MRARSAL---PRSALPRLLLPLLLPAAGP---AQFHGEKG---ISIPDHGFCQ
fz/Dros	ILPTLIQGVQRYDQS---PLDASPYRSGGGLMASSG---TELDG-----LPHHNRCE
fz2/Dros/	GLVLLLTSCRADGPL-----HSADHGMGGMGMGGHGLD-ASPAPGYGVPAPKDPNLRCE

*:

CRD

fz3/mouse	PITLRMCQDLPYNTTFMPNLLNHYDQQTAAALAMEPFHPMVNLDCSRDFRPFLCALYAPIC
fz4/mouse	PIRIAMCQNLGYNVTKMPNLVGHELTDAELQLTTFTPLIQYGCSSQLQFFLCSVYVPMC
fz8/mouse	EITVPLCKGIGYNYTYMPNQFNHDTQDEAGLEVHQFWPLVEIQCSPLKFFLCSMYTPIC
fz5/human	EITVPMCRGIGYNLTHMPNQFNHDTQDEAGLEVHQFWPLVEIQCSPLRFFLCTMYTPIC
fzd9/human	AVEIPMCRGIGYNLTRMPNLLGHTSQGEAAAEAEFAPLVQYGCCHSLRFFLCSLYAPMC
fz1/rat	PISIPLCTDIAYNQTIMPNLLGHTNQEDAGLEVHQFYPLVKVQCSAELKFFLCSMYAPVC
fz2/rat	PISIPLCTDIAYNQTIMPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVC
fz/Dros	PITISICKNIPYNMTIMPNLIGHTKQEEAGLEVHQFAPLVKIGCSSDDLQFLCSLYVPVC
fz2/Dros/	EITIPMCRGIGYNMTSFPNEMNHETQDEAGLEVHQFWPLVEIKCSPLKFFLCSMYTPIC

: : * : * : * : * : * : * : * : * : *

CRD

fz3/mouse	M-EYGRVTLPCRRLCQRAYSECSKLMEMFG-VWPEDMECSRFPDCD-EPYPRLVDLN--
fz4/mouse	TEKINIPIGPCGGMCLSVKRRCEPVLREFG-FAWPDTLNCSKFPPQN-DHNHMCMEGP--
fz8/mouse	LEDYKKPLPPCRSVCERAKAGCAPLMRQYG-FAWPDRMRCDRLEQOG-NPDTLCMDYN-R
fz5/human	LPDYHKPLPPCRSVCERAKAGCSPLMRQYG-FAWPERMSCDRLPVLGRDAEVLCDYN-R
fzd9/human	TDQVSTPIACRPMCEQARLRCAPIMEQFN-FGWPDSLDCARLPTRN-DPHALCMEAPEN
fz1/rat	T-VLEQALPPCRSLCERA-QGCEALMNKFG-FQWPDTLKCEKFPVHG--AGELCVGQNTS
fz2/rat	T-VLEQAIPPCRSICERARQGCEALMNKFG-FQWPERLRCEHFPRHG--AEQICVGQNHSS
fz/Dros	T-ILERPIPPCRSLCESA-RVCEKLMKTYN-FNWPENLECSKFVHG--GEDLCVAENTT
fz2/Dros/	LEDYHKPLPVCRSVCERARSGCAPIMQOYS-FEWPERMACEHLPLHG-DPDNLCMEQPSY

* : * . * ** : * : *

FIG. 2A

3/16

```

fz3/mouse -----LVGDPTE---
fz4/mouse ---GDEE-----VPLPHKTP-
fz8/mouse TDLTTAAPSPPRRLPPPPPPGEQPPSGSGHSRPPGARPPHRGGSSRGSGDAAAAPPSRGG
fz5/human SEATTAPPRP---FPAKP---TLP--G---PP-----G---APAS--GG
fzd9/human ATAGPAEPHK----GLGM---LP-----VAPRPAPPPG
fzl/rat   DKGTPTPSL-----L-----PEFWTSNPQHG
fz2/rat   EDG--TPAL-----L-----TTAPPSGLQPG
fz/Dros   SSA-----STAATPTRSVA
fz2/Dros/ TEAGSGGSSG----GSGG---SGSGSGSGGKRKQGGSGSGGSGAGGSSGSTSTKPCR--GR
amino terminal domain continued

```

```

                                     TM1
fz3/mouse  YSFLHVRDCSPPCPN-----MYFRREELSFARYFIGLISIICLSATLFTFLTFLIDVTR
fz4/mouse  --LNCVLKCGYDAG-----LYSRSAKEFTDIWMAVWASLCFISTTFTVLTLFLIDSSR
fz8/mouse  -KTGQIANCALPCHN-----PFFSQDERAFTVFWIGLWSVLCFVSTFATVSTFLIDMER
fz5/human  -RTGQVPNCAPCYQ-----PSFSADERTFATFWIGLWSVLCFISTSTTVATFLIDMDT
fzd9/human --RSCAPRCGPGVEV-----FWSRRDKDFALVWMAVWSALCFSTFTVLTLFLEPHR
fzl/rat    LGEK---DCGAPCEPTKVYGLMYFGPEELRFSRTWIGIWSVLCCASTLFTVLTYLVDMRR
fz2/rat    LGER---DCAAPCEPARPDGSMFFSHHHTREFARLWILTWSVLCCASTFFTVTTSVLAMQR
fz/Dros    VGGKDLHDCGAPCH-----AMFFPERERTVLRVWVGSAAVCVASCLFTVLTLFLIDSSR
fz2/Dros/  QRIAGVPNCGIPCKG-----PFFSNDEKDFAGLWIALWSGLCF CSTLMTLTTFIIDTER
          *                      :  :  :*      :.  *

```

```

                                     TM2  → extracellular domain loop 1
fz3/mouse  FRYPERPIIFYAVCYMMVSLIFFIGFLE-DRVACNASSP-----
fz4/mouse  FSYPERPIIFLSMCYNIYSIAYIVRLTVGRERISCDF-----
fz8/mouse  FKYPERPFIIFLSACYLFVSVGYLVRLVAGHEKVACSGGAPGAGGRGGAGGAAAAGAGAAG
fz5/human  FRYPERPIIFLSACYLCVSLGFLVRLVVGHASVACS-----
fzd9/human FQYPERPIIFLSMCYNVYSLAFLIRAVAGAQSVACD-----
fzl/rat    FSYPERPIIFLSGCTAVAVAYIAGFLE-DRVVCNDKFAE-----
fz2/rat    FRYPERPIIFLSGCTMVSVAYIAGFVLQ-ERVVCNERFSE-----
fz/Dros    FRYPERAIVFLAVCYLVGCAYVAGLGAG-DSVSCREPFPPPVK---LG-----
fz2/Dros/  FKYPERPFIIFLSACYFMVAVGYLSRNLQNEEIACDG-----
* ****. :.* . ** . :.

```

FIG. 2B

TM3

* * *

fz3/mouse AVPKWGSEAI~~EKKALLFHASAWGIPGTLT~~ILLAMNKIEGDNISGVCFVGLYDVDALRYF
 fz4/mouse AGLKWGHEAIE~~MHSSYFHIAAWAIPAVKTIVILIMRLVDADEL~~TGLCYVGNQNL~~DALTGF~~
 fz8/mouse AGMKWGNEAIA~~GSQYFHLLAAWLVP~~SVKSI~~AVLALSSVDGDPVAGIC~~YVGNQSL~~NLRGF~~
 fz5/human AAMKWGNEAIA~~GSQYFHLLAAWLIP~~SVKSIT~~ALALSSVDGDPVAGIC~~YVGNQNL~~NSLRRF~~
 fz9/human AGKKWGHEAIEA~~HGSYFHMAAWGLP~~ALKTIVIL~~TLRKVAGDEL~~TGLCYVAST~~DAAALTGF~~
 fz1/rat AGMKWGHEAIEA~~NSQYFHLLAAWAVPAIKTITIT~~ALGQVDGDVLSGVCFVGLNNVDALRGF
 fz2/rat AGMKWGHAAIEA~~NSQYFHLLAAWAVPAKTTIT~~ILAMQIDGDL~~LSGVCFVGLNRLDPLRGF~~
 fz/Dros AGLKWGHEAIE~~NKSHLFHLVAVPALQ~~TISVLALAKVEGDILSGVCFVGL~~QDTHSLGAF~~
 fz2/Dros/ AGLKWGNEAIT~~KHSQYFHLLAAWLIP~~TQSVAVLLLSAVDGD~~PILGICYVGNLNP~~DHLKTF
 : ** * : . ** ** * . : * : : . : * : * : *

fz3/mouse VLAPLCLYVVVGVSLLLAGTISLNRVRIETPLEKE-----NQDKLVKFMIRIGVFSILYL
fz4/mouse VVAPLFYTLVIGTFLFAAGLVALFKIRSNLQK-DG----TKTDKLERLMVKIGVFSVLYT
fz8/mouse VLAPLVIYLFIGTMFLLAGFVSLFRIRSVIKQQGGP---TKTHKLEKIMIRLGFTVLYT
fz5/human VLGPLVLVYLLVGTFLFLLAGFVSLFRIRSVIKQ-GG----TKTDKLEKLMIRIGIFTLLYT
fzd9/human VLVPLSGYLVLGSSFLLTGFWALFHIRKIMKT-GG----TNTEKLEKLMVKIGVFSILYT
fzl/rat VLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKH-DG----TKTEKLEKLMVRIGVFSVLYT
fz2/rat VLAPLFVYLFIGTSFLLAGFVSLFRIRTIMKH-DG----TKTEPLERLMVRIGVFSVLYT
fz/Dros LILPLCIYLSIGALFLLAGFISLFRIRTVMKT-DG----KRTDKLERLMLRIGFFSGLFI
fz2/Dros/VLAPLFVYLVIGTTFLMAGFVSLFRIRSVIKQQGGVGAGVKADKLEKLMIRIGIFSIVLYT

: * : : * : . : * :: :

. : :: :: : * *

FIG. 2C

5/16

	TM6	extracellular domain loop 3
fz3/mouse	VPLLVVIGCYFYEQAYRGIWETTWIQERCREYHIPCPYQVTQMS	RPDLILFLM
fz4/mouse	VPATCVIACYFYEISNWALFRYSADDS	NMAVEML
fz8/mouse	VPAAVVVACLFYEQHNRPWEATHNCPCLRDLPDQARR	PDYAVFML
fz5/human	VPASIVVACYLYEQHYRESWEAALTCACPGHDTGQPRAK	PEYWVLM
fzd9/human	VPATCVIVCYVYERLNMDFWRLRATEQPCAAAAGPGGRRDCSLP	GGSVPTVAVFML
fz1/rat	VPATIVIACYFYEQAFRDQERSWVAQSCSYAIPCPHLQGGGGVPPHPPMSPDFTVFM	
fz2/rat	VPATIVIACYFYEQAFREHWERSWVSQHCKSLAIPCPAHYT	PRTSPDFTVYMI
fz/Dros	LPAVGLLGCLFYEYNFDEWMIQWHRDICKPFSIPCPAARAPGS	PEARPIFOIFMV
fz2/Dros/	VPATIVIGCYLYEAAAYFEDWIKALACPCAQVK--GPGKK	PLYSVLM
	* : . . *	::
	TM7	
fz3/mouse	KYLMALIVGIPSIFFWVGSKKTCFEWASFFHGRRKKEIVNESRQVLQEPDFAQSLLRDPNT	
fz4/mouse	KIFMSLLVGITSGMWIWSAKTLHTWQKCS	NRLVNSGKVK---REKRG
fz8/mouse	KYFMCLVVGITSGVWVWSGKTLESWRALC	TRCCWASKGAAVGAGAGGSG
fz5/human	KYFMCLVVGITSGVWVWSGKTVESWRRFT	SRCCCRPR---RGHK
fzd9/human	KIFMSLVVGITSGVWVWSKTFQTWQSLC	YRKIAAGRARA---KACRA
fz1/rat	KYLMTLIVGITSGFWIWSGKTLSWRKFY	TRLTNSK---QGETT
fz2/rat	KYLMTLIVGITSGFWIWSGKTLSWRKFY	TRLTNSR---HGETT
fz/Dros	KYLCMLVGVTSVWVLYSSKTMVSWRNFB	ERLOGKEPRT---RAQAY
fz2/Dros/	KYFMALAVGITSGVWVWSGKTLESWRRFW	RRLGAPDRGTGANQALIKQR
	: : : * : . * : * * :	



FIG. 2D

Sequence alignment of a portion of the aminoterminal extracellular region of human Frizzled receptors

HFZ1	VGQNTSDKGT---PSLLPEFWTSNPQHGGGHRG	GFPGGAG---ASERGFSCPR
HFZ2	VGQNHSEDGA---PALLTTAPPPGLQPGAGGTPG	GPGGGGAPPRYATLEHPFHC
HFZ3	LVDLNLGAG---EPTEGAPV	AVQRDYG---FWC
HFZ4	CMEGPGD---EE	VPLPHKTPI---QP
HFZ5	CMDYNRSEATTAPPRPFAKPTLPG	PPGA---PASGG---ECPAGGPFV---CKC
HFZ6	TEDPHTEF---LGPOKKTE	QVQRDIG---FWC
HFZ7	VGQNTSDGSGGPGGPTAYPTAPYLPDLPTALPPG	ASDGRGRPAF---PFSC
HFZ8	CMDYNRTDLTTAAPSPPRRLP PPP-GEQPPSGSGHGRPPGARPPHRRGGGGRGGGDAAPPARGGGGGKARPPGGGAAP	CEPGCQC
HFZ9	CMEAPENA-TAGPAEPHKGMLPV	APRPARPPG---DLGP
HFZ10	NYLCMEAPNN---GSDEPTRGSGLFPP	LFRPQRPBSAQ---EHP

FIG. 3

6/16

Effect of FZD on SNU1076 cells**FIG. 4****Effect of antibodies SNU 1076 Cells****FIG. 5**

7/16

Graphical Representation of an Olfactory Protein showing Amino-terminal and three Extracellular Domain Loops (from PCT WO 92/17585)




FIG. 7

8/16


Effect of antibodies SNU 1076 Cells

FIG. 6

→ amino terminal domain

HFZ1	MAEEEAPKKSRAAGGGASWELCAGALSARLAEEGSGDAGGRRRPPVDPRLARQLLLLLLW
MFZ1	MAEEAAPSESRAAGR-LSLELCAEALPGRREEVGHEDTASHRRPRADPRRWASGLLLLLLW
HFZ2	-----MRPRSALPRLLLPLL
HFZ3	-----MAMTWIVFSLWPLTV
MFZ3	-----MAVSWIVFDLWLLTV
HFZ4	-----MAWRGAGPSVPGAPGGVGLSLGLLLQ
MFZ4	-----MAWPGTGPSSRGAPGGVGLRLGLLLQ
HFZ5	-----MARPDPSAPPSLL--LLL
HFZ6	-----MEMFTFLITCI
MFZ6	-----MERSPFLLACI
HFZ7	-----MRDPGAAAPLSSSLGLCALVLA
MFZ7	-----MRGPGTAASHSPLGLCALVLA
HFZ8	-----MEWGYLLEVTSLAALAL
MFZ8	-----MEWGYLLEVTSLAALAV
HFZ9	-----MAVAPL-RGALLLWQLLA
MFZ9	-----MAVPPLLRGALLLWQLLA
HFZ10	-----MORPGPRLWLVLQ

FIG. 8A

9/16

HFZ1	LLEAPLLLGVRAQAAGQGPGQGPQGPQPPPPQOOQSGQOYNGERGISVPDHGYCQPIS
MFZ1	LLEAPLLLGVRAQAAGQVSG----PGQQAPPPQPOQSGQOYNGERGISIPDHGYCQPIS
HFZ2	LLPA-----A-----GPAQFHGEKGISIPDHGFCQPIS
HFZ3	FMGHI-----GGHSLFS-----CEPIT
MFZ3	FLGQI-----GGHSLFS-----CEPIT
HFZ4	LLLLLG-----PARGFGDEEE-----RRCDFIR
MFZ4	FLLLLR-----PTLGFGDEEE-----RRCDFIR
HFZ5	LAQLVG-----RAAAASKAPV-----CQEIT
HFZ6	FLPLL-----RGHSLFT-----CEPIT
MFZ6	LLPLV-----RGHSLFT-----CEPIT
HFZ7	LLGAL-----SAGAGAQPYHGEKGISVPDHGFCQPIS
MFZ7	LLGAL-----PTDTRAQPYHGEKGISVPDHGFCQPIS
HFZ8	LQRSSG-----AAAASAKELA-----CQEIT
MFZ8	LQRSSG-----AAAASAKELA-----CQEIT
HFZ9	AGGAAL-----EIGRFDPERGR---GAAPCQAVE
MFZ9	TGGAAL-----EIGRFDPERGR---GPAPCQAME
HFZ10	VMGSCA-----AISSMDMERP---GDGKCQPIE

*:

HFZ1	IPLCTDIAYNOTIMPNNLLGHTNQEDAGLEVHQFYPLVKVQCSAELKFFLCSMYAPVCT-V
MFZ1	IPLCTDMAYNOTIMPNNLLGHTNQEDAGLEVHQFYPLVKVQCSAELKFFLCSMYAPVCT-V
HFZ2	IPLCTDIAYNOTIMPNNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCT-V
HFZ3	LRMCQDLPYNTTFMPNNLLNHYDQQTAAALAMEPFHMPVNLDCSRDFRPFALCALYAPICM-E
MFZ3	LRMCQDLPYNTTFMPNNLLNHYDQQTAAALAMEPFHMPVNLDCSRDFRPFALCALYAPICM-E
HFZ4	ISMCONLGYNVTKMPNLVGHELOTDAELQLTTFTPLIQYGCSSQLQFFLCVYVPMCTEK
MFZ4	IAMCONLGYNVTKMPNLVGHELOTDAELQLTTFTPLIQYGCSSQLQFFLCVYVPMCTEK
HFZ5	VPMCRGIGYNLTHMPNQFNHDTQDEAGLEVHQFWPLVEIQCSPLRFFLCMTYTPICLPD
HFZ6	VPRCMKMAYNMTFFPNLMGHYDQIAAVEMEHFLPLANLECSPNIEFLCKAFVPTCI-E
MFZ6	VPRCMKMTYNMTFFPNLMGHYDQIAAVEMGHFLHLANLECSPNIEFLCQAFIPTCT-E
HFZ7	IPLCTDIAYNOTILPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCT-V
MFZ7	IPLCTDIAYNOTILPNLLGHTNQEDAGLEVHQFYPLVKVQCSPELRFFLCSMYAPVCT-V
HFZ8	VPLCKGIGYNYTYMPNQFNHDTQDEAGLEVHQFWPLVEIQCSPLKFFLCMYTPICLED
MFZ8	VPLCKGIGYNYTYMPNQFNHDTQDEAGLEVHQFWPLVEIQCSPLKFFLCMYTPICLED
HFZ9	IPMCRGIGYNLTRMPNNLLGHTSQGEAAAEALAEFAPLVQYGCCHSLRFFLCVYAPMCTDQ
MFZ9	IPMCRGIGYNLTRMPNNLLGHTSQGEAAQLAEFSPLVQYGCCHSLRFFLCVYAPMCTDQ
HFZ10	IPMCKDIGYNMTRMPNLMGHENQREAAIQHEFAPLVEYGCCHSLRFFLCVYAPMCTEQ

: * : ** * : ** .. * * * : * : : * :.. *** : * *

FIG. 8B

10/16

HFZ1 LEQALPPCRSLCERARQGCEALMNKFGFQWPDTLKCEKFPVHG--AGELCVGQNTSDKGT
 MFZ1 LEQALPPCRSLCERARQGCEALMNKFGFQWPDTLKCEKFPVHG--AGELCVGQNTSDKGT
 HFZ2 LEQAIPPCRSICERARQGCEALMNKFGFQWPERLRCEHFPRHG--AEQICVGQNHSEDA
 HFZ3 YGRVTLPCRRLCQRAYSECSKLMEMFGVPWPEDMECSRFPDCE--EPYPRLVDLNLAG---
 MFZ3 YGRVTLPCRRLCQRAYSECSKLMEMFGVPWPEDMECSRFPDCE--EPYPRLVDLNLVG---
 HFZ4 INIPIGPCGGMCLSVKRRCEPVLKEFGFAWPESLNCSEKFPQON--DHNHMCMEGPGD----
 MFZ4 INIPIGPCGGMCLSVKRRCEPVLREFGFAWPDTLNCSEKFPQON--DHNHMCMEGPGD----
 HFZ5 YHKPLPPCRSVCERAKAGCSPLMRQYGFAPWPERMSCDRLPVLGRDAEVLCDYNRSEATT
 HFZ6 QIHVVPPCRKLCEKVYSDCKKLIDTFGIRWPPEELECRLQYCD--ETVPVTFDPHTEF---
 MFZ6 QIHVVLPCKRLCEKIVSDCKKLMDTFGIRWPPEELECRLPHCD--DTVPVTSHPHTEL---
 HFZ7 LDQAIPPCRSICERARQGCEALMNKFGFQWPERLRCEHFVHG--AGEICVGQNTSDGSG
 MFZ7 LDQAIPPCRSICERARQGCEALMNKFGFQWPERLRCEHFVHG--AGEICVGQNTSDGSG
 HFZ8 YKKPLPPCRSVCERAKAGCAPLMRQYGFAPWDRMRCRLPEQG--NPDTLCMDYNRTDLTT
 MFZ8 YKKPLPPCRSVCERAKAGCAPLMRQYGFAPWDRMRCRLPEQG--NPDTLCMDYNRTDLTT
 HFZ9 VSTPIACRPMCEQARLRCAPIMEQFNFGWPDSDLCARLPTRN--DPHALCMEAPENA-TA
 MFZ9 VSTPIACRPMCEQARLRCAPIMEQFNFGWPDSDLCARLPTRN--DPHALCMEAPENA-TA
 HFZ10 VSTPIACRVMCEQARLKCSPIEQFNFKWPDSDLCKRLPNKN--DPNYLCMEAPNN----

. * : * * : : * : : *

HFZ1 PT---PSLLPEFWTSNPQHGGGGHGRG-----
 MFZ1 PT---PSLLPEFWTSNGQHGGGGYRG-----
 HFZ2 ----PALLTTAPPPGLQPGAGGTPG-----
 HFZ3 ---EPTEGAPV-----A
 MFZ3 ---DPTEGAPV-----A
 HFZ4 ----EE-----V
 MFZ4 ----EE-----V
 HFZ5 APPRPFFAKPTLPG-----PPGA-----PASGG-----
 HFZ6 ---LGPQKKTE-----Q
 MFZ6 ---SGPQKKSD-----Q
 HFZ7 GPGGGPTAYPTAPYLPDLPTALPPG-----
 MFZ7 GAGGSPTAYPTAPYLPDPPTAMSP-----
 HFZ8 AAPSPPRRLPPPPP-GEQPPSGSGHGRPPGARPPHRGGGRGGGGDAAAPPARGGGGGK
 MFZ8 AAPSPPRRLPPPPPPGEQPPSGSGHSRPPGARPPHRGGSSRSGSDAAAAPPSRGG----K
 HFZ9 GPAEPHKGLGMLPV-----A
 MFZ9 GPTEPHKGLGMLPV-----A
 HFZ10 GSDEPTRGSGLFPP-----L

FIG. 8C

11/16

HFZ1 GPPGGAG----ASERKGFSCPRALKVPSYLNHFLGEKDCGAPCEPTKVYGLMYFGPEEL
 MFZ1 GYPGGAG----TVERGKFSCPRALRVPSYLNHFLGEKDCGAPCEPTKVYGLMYFGPEEL
 HFZ2 GPGGGGAPPRYATLEHPFHCPVLKVPSYLSYKFLGERDCAAPCEPARPDGSMFFSQEET
 HFZ3 VQRDYG-----FWCPRELKIDPDLGYSFLHVRDCSPPCP----NMYFR--REEL
 MFZ3 VQRDYG-----FWCPRELKIDPDLGYSFLHVRDCSPPCP----NMYFR--REEL
 HFZ4 PLPHKTPI-----QPGECHSVGTNSDQYIWVKRSLNCVLKCGYDAGLY-SRSAK
 MFZ4 PLPHKTPI-----QPGECHSVGSNSDQYIWVKRSLNCVLKCGYDAGLY-SRSAK
 HFZ5 ECPAGGPFV-----CKCREPFVPILKESHPLYNKVRTGQVPNCAVPCYOPSFSADER
 HFZ6 VQRDIG-----FWCPRHLKTSGGQGYKFLGIDQCAPP CP----NMYFK--SDEL
 MFZ6 VPRDIG-----FWCPKHLRTSGDQGYRFLGIEQCAPP CP----NMYFK--SDEL
 HFZ7 ASDGRGRPAF-----PFSCPRQLKVPYPYLGYRFLGERDCGAPCEPGRANGLMYFKEEER
 MFZ7 -SDGRGRLSF-----PFSCPRQLKVPYPYLGYRFLGERDCGAPCEPGRANGLMYFKEEER
 HFZ8 ARPPGGGAAP---CEPGCQCRAPMVSVSSEHPLYNRVKTGQIANCALPCHNPFFSQDER
 MFZ8 ARPPGGGAAP---CEPGCQCRAPMVSVSSEHPLYNRVKTGQIANCALPCHNPFFSQDER
 HFZ9 PRPARPPG-----DLGPGAGGSGTCENPEKFQYVEKSRSCAPRCGPGVEVFWSRRDK
 MFZ9 PRPARPPG-----DSAPGPGSGGTCNPEKFQYVEKSRSCAPRCGPGVEVFWSRRDK
 HFZ10 FRPQRPHSAQ----EHPLKDGPGRGGCDNPGKFHHVEKSASCAPLCTPGVDVYWSREDK

HFZ1 RFSRTWIGIWSVLCCASTLFTVLTLYLDMRRFSYPERPIIFLSGCTAVAVAYIAGFLL
 MFZ1 RFSRTWIGIWSVLCCASTLFTVLTLYLDMRRFSYPERPIIFLSGCTAVAVAYIAGFLL
 HFZ2 RFARLWILTWSVLCCASTFTTFTVLTLYLDMRRFSYPERPIIFLSGCTAVAVAYIAGFLL
 HFZ3 SFARYFIGLISIICLSATLFTFLTLIDVTRFRYPERPIIFYAVCYMMVSLIFFIGFLL
 MFZ3 SFARYFIGLISIICLSATLFTFLTLIDVTRFRYPERPIIFYAVCYMMVSLIFFIGFLL
 HFZ4 EFTDIWMAVWASLCFISTFTVLTFLIDSSRFSYPERPIIFLSMCYNIYSIAYIVRLTVG
 MFZ4 EFTDIWMAVWASLCFISTFTVLTFLIDSSRFSYPERPIIFLSMCYNIYSIAYIVRLTVG
 HFZ5 TFATFWIGLWSVLCFISTTFTVLTFLIDMDTFRYPERPIIFLSACYLCVSLGFLVRLVVG
 HFZ6 EFAKSFIGTVSIFCLCATLFTFLTLIDVRRFRYPERPIIYYSVCYSIVSLMYFIGFLLG
 MFZ6 DFAKSFIGIVSIFCLCATLFTFLTLIDVRRFRYPERPIIYYSVCYSIVSLMYFVGFLLG
 HFZ7 RFARLWVGWWSVLCCASTLFTVLTLYLDMRRFSYPERPIIFLSGCTAVAVAHVAGFLL
 MFZ7 RFARLWVGWWSVLSASTLFTVLTLYLDMRRFSYPERPIIFLSGCTAVAVAHVAGFLL
 HFZ8 AFTVFWIGLWSVLCFVSTFATVSTFLIDMERFKYPERPIIFLSACYLFVSVGYLVRLVAG
 MFZ8 AFTVFWIGLWSVLCFVSTFATVSTFLIDMERFKYPERPIIFLSACYLFVSVGYLVRLVAG
 HFZ9 DFALVWMAVWSALCFFSTFTVLTFLLEPHRFQYPERPIIFLSMCYNVYSLAFLIRAVAG
 MFZ9 DFALVWMAVWSALCFFSTFTVLTFLLEPHRFQYPERPIIFLSMCYNVYSLAFLIRAVAG
 HFZ10 RFVAVWLAIWAVLCFFSSAFTVLTFLIDPARFRYPERPIIFLSMCYCVYSGYLIRLFA

*: :: :. :. *. *.*: * ***** : ** :: ..

FIG. 8D

13/16

↔ extracellular domain loop 2 ↔

HFZ1	ITILALGQVDGDVLSGVCVGLNNDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTI
MFZ1	ITILALGQVDGDVLSGVCFLGLNNDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTI
HFZ2	ITILAMGQIDGDLISGVCVGLNSLDPLRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTI
HFZ3	IILLAMNKIEGDNISGVCVGLYDLDALRYFVLAPLCLYVVVGVSLLLAGIISLNRVRIE
MFZ3	IILLAMNKIEGDNISGVCVGLYDLDALRYFVLAPLCLYVVVGVSLLLAGIISLNRVRIE
HFZ4	IVILIMRLVDADELTGLCYVGNQNLDAITGFVAPLFTYLVIGTLFIAAGLVALFKIRSN
MFZ4	IVILIMRLVDADELTGLCYVGNQNLDAITGFVAPLFTYLVIGTLFIAAGLVALFKIRSN
HFZ5	ITALALSSVDGDPVAGICYVGNQNLRLRRFVLGPLVLYLVGTLFLLAGFVSLFRIRSV
HFZ6	VMLLAMNKVEGDNISGVCVGLYDLDASRYFVLLPLCLCVFVGLSLLLAGIISLNVHRQV
MFZ6	VMLLAMNKVEGDNISGVCVGLYDLDASRYFVLLPLCLCVFVGLSLLLAGIISLNVHRQV
HFZ7	ITILAMGQVDGDLISGVCVGLSSVDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTI
MFZ7	ITILAMGQVDGDLISGVCVGLSSVDALRGFVLAPLFVYLFIGTSFLLAGFVSLFRIRTI
HFZ8	IAVLALSSVDGDPVAGICYVGNQSLDLNRGFVLAPLVIYLFIGTMFLLAGFVSLFRIRSV
MFZ8	IAVLALSSVDGDPVAGICYVGNQSLDLNRGFVLAPLVIYLFIGTMFLLAGFVSLFRIRSV
HFZ9	IVILTLRKVAGDELTGLCYVASTDAAALTGFVLVPLSGYLVLGSSFLLTGFVALFHIRKI
MFZ9	IVVLTLRKVAGDELTGLCYVASMDPAALTGFVLVPLSCYLVLGTSFLLTGFAVALFHIRKI
HFZ10	ILILVMRRVAGDELTGVCYVGSMDVNALTGFVLIPLACYLVIGTSFILSGFVALFHIRRV

: * : : . * : * : * : . . ** : ** : : * : : : * : * : *

↔ extracellular domain loop 3

HFZ1	MKH--DGTKTEKLEKLMVRIGVFSVLYTVPATIVIACYFYEQAFRDQWERSWVAQSCSKSY
MFZ1	MKH--DGTKTEKLEKLMVRIGVFSVLYTVPATIVIACYFYEQAFRDQWERSWVAQSCSKSY
HFZ2	MKH--DGTKTEKLERLMVRIGVFSVLYTVPATIVIACYFYEQAFREHWERSWVSQHCKSL
HFZ3	IPL--EKENQDKLVKFMIRIGVFSILYLVPLLVLVIGCYFYEQAYRGIWETTIIQERCREY
MFZ3	IPL--EKENQDKLVKFMIRIGVFSILYLVPLLVLVIGCYFYEQAYRGIWETTIIQERCREY
HFZ4	LQK--DGTKTDKLERLMVKIGVFSVLYTVPATCVIACYFYEISNWALFRYSADDSNMAV-
MFZ4	LQK--DGTKTDKLERLMVKIGVFSVLYTVPATCVIACYFYEISNWALFRYSADDSNMAV-
HFZ5	IKQ--GGTKTDKLEKLMIRIGIFTLLYTVPASIVVACYLYEQHYRESWEAALTCACPGHD
HFZ6	IQH--DGRNQEKLLKFMIRIGVFSGLYLVPLVTLGCVVYEQVNRTWETITWVSDHCROY
MFZ6	IQH--DGRNQEKLLKFMIRIGVFSGLYLVPLVTLGCVVYELVNRTWEMTWFSCHQY
HFZ7	MKH--DGTKTEKLEKLMVRIGVFSVLYTVPATIVIACYFYEQAFREHWERTWLLQTCKSY
MFZ7	MKH--DGTKTEKLEKLMVRIGVFSVLYTVPATIVIACYFYEQAFREHWERTWLLQTCKSY
HFZ8	IKQDGPPTKTHKLEKLMIRLGLFTVLYTVPAVVVACLFYEQHNRPRWEATHNCPCLRDL
MFZ8	IKQDGPPTKTHKLEKLMIRLGLFTVLYTVPAVVVACLFYEQHNRPRWEATHNCPCLRDL
HFZ9	MKT--GGTNTKLEKLMVKIGVFSILYTVPATCVIVCYVYERLNMDFWRLRATEQPCTAA
MFZ9	MKT--GGTNTKLEKLMVKIGVFSILYTVPATCVIVCYVYERLNMDFWRLRATEQPCTAA
HFZ10	MKT--GGENTDKLEKLMVRIGLFSVLYTVPATCVIACYFXEHLNMDYWKILAAQHKCKM-

: : : . ** : * : * : * : * : * : * : * : * : *

FIG. 8F

14/16

←1

HFZ1	AIPCPHLQAGGGAPPHPPMSPDFTVFMKYLMTLIVGITSQFWIWSGKTLNSWRKFYTRL
MFZ1	AIPCPHLQGGGVPPHPPMSPDFTVFMKYLMT-----LNSWRKFYTRL
HFZ2	AIPCP-----AHYTPR--MSPDFTVYMIKYLMTLIVGITSQFWIWSGKTLHSWRKFYTRL
HFZ3	HIPCP-----YQVTQMSRPDLILFLMKYLMALIVGIPSVFWVGSKKTCEWASFFHGR
MFZ3	HIPCP-----YQVTQMSRPDLILFLMKYLMALIVGIPSIWFVGSKKTCEWASFFHGR
HFZ4	-----EMLKIFMSLLVGITSGMWIWSAKTLHTWQ-KCSNR
MFZ4	-----EMLKIFMSLLVGITSGMWIWSAKTLHTWQ-KCSNR
HFZ5	TGQPR---AK-----PEYWVLMKYFMCLVVGITSGVWWSGKTVESWRFTSRC
HFZ6	HIPCP-----YQAKAKARPELALFMKYLMTLIVGISAVFWVGSKKTCEWAGFFKRN
MFZ6	RIPCP-----YQANPKARPELALFMKYLMTLIVGISAVFWVGSKKTCEWAGFFKRN
HZF7	AVPCP---PGHFPPM---SPDFTVFMKYLMTMIVGITTGFWIWSGKTLQSWRRFYHRL
MFZ7	AVPCP---PRHFSPM---SPDFTVFMKYLMTMIVGITTGFWIWSGKTLQSWRRFYHRL
HFZ8	QPDQA---RR-----PDYAVFMLKYFMCLVVGITSGVWWSGKTLESWSRLCTRC
MFZ8	QPDQA---RR-----PDYAVFMLKYFMCLVVGITSGVWWSGKTLESWRALCTRC
HFZ9	AGPGG---RRDCSLPGGSVPTVAVFMLKIFMSLVVGITSGVWWSKTFQTWQSLCYRK
MFZ9	TVPGG---RRDCSLPGGSVPTVAVFMLKIFMSLVVGITSGVWWSKTFQTWQSLCYRK
HFZ10	NNQTK---TLDC-LMAASIPAVEIFMVKIFMLLVVGITSGMWIWTSKTLQSWQOVCSRR

::* :*

*

HFZ1	TN--SKOGETTV-----
MFZ1	TN--SKOGETTV-----
HFZ2	TN--SRHGETTV-----
HFZ3	RKKEIVNESRQVLQEP-----DFAQSLLRDPNTPIIRKSRGTSTQGTSTHAS
MFZ3	RKKEIVNESRQVLQEP-----DFAQSLLRDPNTPIIRKSRGTSTQGTSTHAS
HFZ4	LVNSGKVKREKRGNGW-----VKPGKGSE-----
MFZ4	LVNSGKVKREKRGNGW-----VKPGKGNE-----
HFZ5	CC-RPRRGHKSGGA-----MA--AG-D-----
HFZ6	RKRDPISESRRVLQESCEFFLKHNSKVHKKKKHYKPSSHLKLVISKSMGTSTGATANHGT
MFZ6	RKRDPISESRRVLQESCEFFLKHNSKVHKKKKHGAPGPHRLKLVISKSMGTSTGATTNHGT
HFZ7	SH--SSKGETAV-----
MFZ7	SH--SSKGETAV-----
HFZ8	CW-ASKGAAVGGGAGA-----TAAGGGGGPGGGGGGP
MFZ8	CW-ASKGAAVGAGAGG-----SGPGGSGP-----GP
HFZ9	IA--AGRARAKACRAP-----GSYGRGTHC-----
MFZ9	MA--AGRARAKACRTP-----GGYGRGTHC-----
HFZ10	LKKKSRRKPASVITSG-----GIYKKAQH-----

FIG. 8G

15/16

HFZ1 -----
MFZ1 -----
HFZ2 -----
HFZ3 STQLAMVDDQRSKAGSIHVKVSSYHGSLHRSRDGRYTPCSYRG--MEERLPHGSMS-RLT
MFZ3 STQLAMVDDQRSKAGSVHVKVSSYHGSLHRSRDGRYTPCSYRG--MEERLPHGSMS-RLT
HFZ4 -----TVV-----
MFZ4 -----TVV-----
HFZ5 -----YPEASAALTGRTGPPGPAATYHKQVSLSHV-----
HFZ6 SAVAITSHDYLQETLITEIQTSPESTMREVKADGASTPRLREQDCGEPASPAASIS-RLS
MFZ6 SAMAIADHDYLQETSTEVTSTPEASVKEGRADRANTPSAKDRDCGESAGPSSKLSGNRN
HFZ7 -----
MFZ7 -----
HFZ8 GGGGGPGGGGSLYSDVSTGLTWRSGTAS-SVSYPKQMPLSQV-----
MFZ8 GGGGGHGGGGSLYSDVSTGLTWRSGTAS-SVSYPKQMPLSQV-----
HFZ9 -----H---YKAPTIVLHMTKTDPSLENPTHL-----
MFZ9 -----H---YKAPTIVLHMTKTDPSLENPTHL-----
HFZ10 -----PQKT-HHGKYEIPAQSPTCV-----

HFZ1 -----
MFZ1 -----
HFZ2 -----
HFZ3 DHSRHSSSHRLNEQSRHSSIRDLSNNPMTHITHGTSMNRVIEEDG TSA-----
MFZ3 DHSRHSSSHRLNEQSRHSSIRDLSNNPMTHITHGTSMNRVIEEDG TSA-----
HFZ4 -----
MFZ4 -----
HFZ5 -----
HFZ6 GEQVDGKG--QAGSVSESARSEGRISPKSDITDTGLAQSNLQVPSSSEPSSLKGSTSL
MFZ6 GRESRAGGLKERSNGSEGAPSEGRVSPKSSVPETGLIDCSTSAASSPEPTSLKGSTSLP
HFZ7 -----
MFZ7 -----
HFZ8 -----
MFZ8 -----
HFZ9 -----
MFZ9 -----
HFZ10 -----

FIG. 8H

16/16

HFZ1	-----
MFZ1	-----
HFZ2	-----
HFZ3	-----
MFZ3	-----
HFZ4	-----
MFZ4	-----
HFZ5	-----
HFZ6	VHPVSGVRKEQGGGCHSDT
MFZ6	VHSASRARKEQGAGSHSDA
HFZ7	-----
MFZ7	-----
HFZ8	-----
MFZ8	-----
HFZ9	-----

FIG. 8I

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
21 November 2002 (21.11.2002)

PCT

(10) International Publication Number
WO 02/092635 A3

- (51) International Patent Classification⁷: **C07K 16/28**, 16/30, C12N 15/12, A01K 67/027, C12N 15/79, 5/10, A61K 39/395, C07K 19/00, A61P 35/00, G01N 33/50
- (74) Agents: **SEPERACK, Peter, K et al.**; Townsend And Townsend And Crew LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111-3834 (US).
- (21) International Application Number: **PCT/IB02/02887**
- (22) International Filing Date: **1 May 2002 (01.05.2002)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
09/847,102 **1 May 2001 (01.05.2001)** **US**
- (71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Transfer, 12th Floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).
- (72) Inventors: **RHEE, Chae-Seo**; 12510 Carmel Creek Road, San Diego, CA 92130 (US). **SEN, Malini**; 3455 Lebon Drive, #1635, San Diego, CA 92122 (US). **LEONI, Lorenzo, M.**; 3908 Via Tranquilo, San Diego, CA 92122 (US). **CORR, Maripat**; 10686 Mira Lago Terrace, San Diego, CA 92131 (US). **CARSON, Dennis, A.**; 14824 Vista Del Oceano, Del Mar, CA 92014 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— *with international search report*
- (88) Date of publication of the international search report:
25 September 2003

[Continued on next page]

(54) Title: IMMUNOLOGIC COMPOSITIONS AND METHODS FOR STUDYING AND TREATING CANCERS EXPRESSING FRIZZLED ANTIGENS

Sequence alignment of a portion of the aminoterminal extracellular region of human Frizzled receptors

HFZ1	VGQNTSDKGT---PSLLPEFWTSNPQHGGGHRG-----	GFPGAG---ASERGFSCPR
HFZ2	VGQNHSEDCG----PALITAPPGLQPGAGGTPG-----	GPGGGAPPRIATLEHPFHC
HFZ3	LVDLNLG-----EPTGAPV-----	AVQRDYG-----FWC
HFZ4	CMEGPGD-----EE-----	VPLPHKTPI-----QP
HFZ5	CMQYNRSEATTAPRPFPKPTLP-----PPGA-----	PASGG---ECPAGGPFV-----CKC
HFZ6	TFDPHTEF-----LGPKKTE-----	QVQRDIG-----FWC
HFZ7	VGQNTSDGSGGPGGPTAYPTAPYLPDLPTALPPG-----	ASDGRGRPAF-----PFSC
HFZ8	CMQYNRTDLTTAAPSPPRRLLPPPP-GEQPPSGSGHGRPPGARPPHGGGRGGGGDAAAPPARGGGGGKARPPGGGAAP---	CEPGCQC
HFZ9	CNEAPENA-TAGPAEPHKGGLMLPV-----	APRPAPPG-----DLGP
HFZ10	NYLCMEAPNN---GSDEPTRGSGLEPP-----	LFRPQRPHSAQ---EHP

(57) Abstract: This invention is in the field of immunology. More specifically, it relates to compositions and methods for identifying, treating and preventing cancer by targeting the extracellular domains of the frizzled receptor family of proteins.

WO 02/092635 A3

[illegible]

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/02887

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K16/28 C07K16/30 C12N15/12 A01K67/027 C12N15/79
C12N5/10 A61K39/395 C07K19/00 A61P35/00 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>TOKUHARA M ET AL: "Molecular cloning of human ---Frizzled--- -6" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, 1998, XP002074753 ISSN: 0006-291X figure 1</p> <p style="text-align: center;">--- -/-</p>	11-15

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

17 June 2003

Date of mailing of the international search report

02/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Wagner, R

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SAGARA N ET AL: "MOLECULAR CLONING, DIFFERENTIAL EXPRESSION, AND CHROMOSOMAL LOCALIZATION OF HUMAN FRIZZLED-1, FRIZZLED-2, AND FRIZZLED-7" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 252, 1998, pages 117-122, XP000882774 ISSN: 0006-291X figure 2	11-15
Y	POLAKIS P: "Wnt signaling and cancer" GENES AND DEVELOPMENT, COLD SPRING HARBOR LABORATORY PRESS, NEW YORK, US, vol. 14, no. 15, 1 August 2000 (2000-08-01), pages 1837-1851, XP002240708 ISSN: 0890-9369 page 1838	26
Y	WO 99 26960 A (MILLENNIUM PHARM INC) 3 June 1999 (1999-06-03) page 64 -page 71 page 9	26
P,X	WEERARATNA ASHANI T ET AL: "Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma." CANCER CELL, vol. 1, no. 3, April 2002 (2002-04), pages 279-288, XP002244429 April, 2002 ISSN: 1535-6108 page 283	1,16-18
A	"Membrane Receptors: Frizzled and related proteins" SANTA CRUZ BIOTECHNOLOGY, ONLINE CATALOGUE, 'Online! XP002244430 Retrieved from the Internet: <URL:http://www.scbt.com/catalog/action.la sso?-database=intros2003&-layout=main&-response=toc_subsection.html&-recordID=38067&-token.order_id=1630401&-search> 'retrieved on 2003-06-16! the whole document	1-10, 16-26
A	EP 1 001 023 A (SMITHKLINE BEECHAM PLC) 17 May 2000 (2000-05-17) the whole document	1-26
	--- -/-	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 02/02887

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MALIK J H ET AL: "STRUCTURE AND EXPRESSION OF A NOVEL FRIZZLED GENE ISOLATED FROM THE DEVELOPING MOUSE GUT" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 349, 2000, pages 829-834, XP002934763 ISSN: 0264-6021 page 834</p> <p>---</p>	1-26
A	<p>TANAKA S ET AL: "A NOVEL FRIZZLED GENE IDENTIFIED IN HUMAN ESOPHAGEAL CARCINOMA MEDIATES APC/BETA-CATENIN SIGNALS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 95, August 1998 (1998-08), pages 10164-10169, XP002190857 ISSN: 0027-8424 page 10167 -page 10169</p> <p>---</p>	1-26
A	<p>VAN GIJN MARIELLE E ET AL: "Overexpression of components of the Frizzled-Dishevelled cascade results in apoptotic cell death, mediated by beta-catenin." EXPERIMENTAL CELL RESEARCH, vol. 265, no. 1, 15 April 2001 (2001-04-15), pages 46-53, XP002244431 ISSN: 0014-4827 page 47</p> <p>---</p>	1-26
A	<p>WO 01 12808 A (CHUGAI RES INST FOR MOLECULAR ; NUMATA MARIKO (JP); SENOO CHIAKI (J) 22 February 2001 (2001-02-22) abstract</p> <p>-----</p>	1-26

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/02887

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 17,23,24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 02/02887

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9926960	A	03-06-1999	AU	1535899 A	15-06-1999
			WO	9926960 A2	03-06-1999
EP 1001023	A	17-05-2000	EP	1001023 A2	17-05-2000
			JP	2000093186 A	04-04-2000
			US	2002137129 A1	26-09-2002
WO 0112808	A	22-02-2001	AU	6596600 A	13-03-2001
			WO	0112808 A1	22-02-2001